

34th MALAYSIAN UROLOGICAL CONFERENCE 2025

Innovating Urology INSPIRING CARE

20 NOVEMBER 2025

Precongress Masterclass

21-22 NOVEMBER 2025

Main Congress

VENUE

Pullman Hotel, Kuching
Sarawak





HELP YOUR PATIENTS WITH OAB

BENEFIT

FROM
TREATMENT
WITH BETA-3
AGONISTS



Betmiga™
mirabegron
Elevate OAB control

Beta-3 agonists such as BETMIGA™ can help avoid the side-effects of antimuscarinics while providing optimal symptom relief



OAB, overactive bladder; QoL, quality of life.

References : 1. Nitti VW, et al. J Urol. 2013;189:1388-1395. 2. Kelleher C, et al. European urology. 2018;74(3):324-333. 3. Chapple C, et al. European urology. 2015;67(1):11-4. 4. Drake MJ, et al. European urology. 2016;70(1):136-45. 5. Lozano-Ortega G, et al. Drugs Aging. 2020;37:801-816. 6. Nazir J, et al. Pharmacoecon Open. 2017;1:25-36. 7. Kato D, et al. Low Urin Tract Symptoms. 2019;11:O152-O161. 8. Soda T, et al. Neurourol Urodyn. 2020;39:2527-2534. 9. Andersson KE, et al. Ther Adv Urol. 2018;10:243-256. 10. Chapple CR, et al. Int Urogynecol J. 2013;24:1447-1458. 11. Freeman R, et al. Curr Med Res Opin. 2018;34:785-793.

Scan the QR code
for BETMIGA™ API



Astellas Pharma Malaysia Sdn. Bhd.
Unit 9.02 and 9.03, Level 9, Corporate Tower 2,
Pavilion Damansara Heights, 3, Jalan Damanlela,
Pusat Bandar Damansara 50490 Kuala Lumpur
Tel: +603-2202 6999 | www.astellas.com
© 2025 Astellas. All rights reserved.

MAT-MY-BET-2025-00081

Content

Welcome Messages	
– The Organising Chairman	5
– The Chairman of the Scientific Programme	6
– The President of the Malaysian Urological Association	7
Organising Committee	9
Malaysian Urological Association – Executive Committee	
Invited Faculty	10
PRE-CONGRESS SEMI-LIVE SURGERY	11
NURSES' ROBOTIC SYMPOSIUM	12
 <u>Daily Programme</u>	
FRIDAY, 21 NOVEMBER 2025	15
SATURDAY, 22 NOVEMBER 2025	17
 UROLOGY NURSING SYMPOSIUM	 19
SPEAKERS PROFILE	
– Local	21
– Invited	29
Speakers Abstract	39
Exhibition Floor Plan	46
Exhibitors Profile	47
Conference Information	60
Acknowledgement	62

Conference Secretariat

34th Malaysian Urological Conference
Malaysian Urological Association

Unit 6-5, Bangunan Perdagangan D6, 801 Jalan Sentul, 51000 Kuala Lumpur, Malaysia
Email: malaysianurologicalassociation@gmail.com
Website: www.muc2025.com

LUTS/BPH adversely affects individual's QoL¹

When there is a choice....

Why take the risk?

Start today for a better tomorrow

Initiate Duodart for the symptomatic relief he needs
and lower risk of progression events* he deserves

BPH
related
AUR

Compromised
quality
of life

Symptom
deterioration

DUODART

DUODART
(dutasteride/tamsulosin HCl) Capsules

*Incidence of AUR/S at 4 years

Why take the risk?

DUODART
(dutasteride/tamsulosin HCl) Capsules

Duodart: Improving patient lives for more than a decade²



11,868 patients studied in
landmark trials

- with 6909 patients on dutasteride, as
monotherapy and in combination with
tamsulosin^{*2-7}



Estimated **10.7 million**
patient-years cumulative
post-marketing exposure²



CRSF packaging:

Capsules packaged in a child-resistant
senior-friendly bottle⁸



Available in **88 countries**^{** 2}

Footnotes:*The overall number of patients studied in landmark trials is 11,868 with Phase III: 4325; EPICS: 1630; SMART: 327; CombAT: 4844; CONDUCT: 742. The number of patients studied in landmark trials with dutasteride as monotherapy or in combination with tamsulosin is 6,909 with Phase III: 2167; EPICS: 813; SMART: 327; CombAT: 3233; CONDUCT: 369.

******In some countries, Duodart may be registered under other trade names, e.g. Combodart, Doubluts, Jalyn, Duagen, dutasteride-tamsulosin GSK, Jelnu or Juteo. Cumulative patient-years of exposure is the sum of the years that each patient was exposed to the medication, totalled for all patients since registration until March 2022.

Duodart Safety Information⁹

Duodart is contraindicated in patients with a history of orthostatic hypotension, severe hepatic impairment, women, patients. ≤ 21 years old, hypersensitivity to tamsulosin, dutasteride, other ingredients of the product or to other 5 α -reductase inhibitors. The effects of hepatic impairment on the pharmacokinetics of dutasteride have not been investigated. As dutasteride undergoes extensive metabolism and has a half-life of 3-5 weeks, Duodart should be used with caution in patients with mild to moderate hepatic impairment. Common adverse events ($\geq 1/100$ and $< 1/10$) include impotence, decreased libido, ejaculation disorders, breast tenderness, and dizziness.

Reference:

1. GBD 2019 Benign Prostatic Hyperplasia Collaborators. Lancet Healthy Longev 2022;3(11):e754–e776.
2. GSK data on file 2022N517027_00 August 2022.
3. Roehrborn CG, Perez IO, Roos EPM, *et al.* Efficacy and safety of a fixed-dose combination of dutasteride and tamsulosin treatment (Duodart®) compared with watchful waiting with initiation of tamsulosin therapy if symptoms do not improve, both provided with lifestyle advice, in the management of treatment-naïve men with moderately symptomatic benign prostatic hyperplasia: 2-year CONDUCT study results. BJU Int. 2015; 116:450-459.
4. Roehrborn CG, Siami P, Barkin J, *et al.* The effects of combination therapy with dutasteride and tamsulosin on clinical outcomes in men with symptomatic benign prostatic hyperplasia: 4-year results from the CombAT study. Eur Urol. 2010; 57:123–131.
5. Roehrborn CG, Boyle P, Nickel JC, *et al.* hyperplasia. Urology 2002 Sep;60(3):434-41. doi: 10.1016/s0090-4295(02)01905-2.
6. Barkin J, Guimarães M, Jacobi G, *et al.* Alpha-blocker therapy can be withdrawn in the majority of men following initial combination therapy with the dual 5 α -reductase inhibitor dutasteride. Eur Urol. 2003; 44:461-466.
7. Debruyne F, Barkin J, van Erps P, *et al.* Efficacy and safety of long-term treatment with the dual 5 α -reductase inhibitor dutasteride in men with symptomatic benign prostatic hyperplasia. Eur Urol. 2004; 46:488-494.
8. GSK data on file 2020N449693_00 August 2020.
9. Duodart Prescribing Information.



For Malaysia Healthcare Professionals Only
PM-MY-DTT-BTHC-230004 04/25

Before prescribing, please refer to the full prescribing information,
which is available via scanning this QR code.
For any issues accessing the prescribing information via QR code,
please contact GSK Malaysia at medinfo.my@gsk.com.

Trade marks are owned by or licensed to the GSK group of companies.
©2025 GSK group of companies or its licensor.

GlaxoSmithKline Pharmaceutical Sdn Bhd
195801000141(3277-U)
HZ.01, Horizon Penthouse, 1 Powerhouse, 1, Persiaran Bandar Utama,
Bandar Utama, 47800 Petaling Jaya, Selangor Darul Ehsan, Malaysia
Tel: (603) 2037 9808 www.my.gsk.com

Message

FROM THE

Organising Chairman

34th MALAYSIAN UROLOGICAL CONFERENCE 2025



Dear Delegates and Esteemed Guests,

On behalf of the Malaysian Urological Association (MUA), it is my great pleasure to welcome you to the 34th Malaysian Urological Conference (MUC 2025), being held for the third time in the beautiful city of Kuching, Sarawak. We are honored to host this prestigious event at the Pullman Kuching Hotel from 20th to 22nd November 2025.

This year's MUC promises to be an academically enriching experience, with a carefully curated programme that brings together a diverse panel of local and international experts. We are excited to provide you with insightful discussions, cutting-edge research, and innovative approaches to urology. We are confident that this conference will inspire you professionally, as well as foster collaboration among urologists, surgeons, oncologists, and allied health professionals from across the region.


In addition to the academic engagement, we are also delighted to introduce you to the rich cultural heritage and stunning natural beauty of Sarawak. From the lush rainforests to the vibrant traditions of the local communities, there is much to explore and enjoy during your time here. Sarawak offers a perfect blend of modernity and tradition, with its unique culture, cuisine, and warm hospitality making it a memorable destination for all.

We look forward to welcoming you to Kuching and hope you have a rewarding and enjoyable experience at MUC 2025. Together, let us make this conference not only a milestone in urological advancements but also an unforgettable journey through the heart of Sarawak.

Warm regards,

Dr Aaron Goh Yue Keng

Organizing Chairman, MUC 2025
34th Malaysian Urological Conference 2025



Message

FROM THE

Chairman of the Scientific Programme



Dear Friends, Delegates and Esteemed Guest,

It is my great pleasure and honour to welcome you to the 34th Malaysian Urological Conference (MUC 2025), which will be held from 20th to 22nd November 2025 in the vibrant city of Kuching, Sarawak.

As we gather under the theme “Innovating Urology, Inspiring Care,” our aim is to create a platform where forward-thinking ideas meet practical application. This year’s scientific programme is thoughtfully designed to spark dialogue, challenge conventional approaches, and highlight emerging trends in urological care.

We have curated a diverse agenda featuring plenary sessions, semi live and hands-on workshops, multidisciplinary forums, and focused symposia—ensuring that there is something meaningful for every member of the urological community.


Beyond the conference hall, I encourage you to explore the unique charm of Kuching and immerse yourself in the rich heritage of Sarawak. From vibrant local cuisine to colourful cultural performances and breath-taking natural landscapes, your time here promises not only professional enrichment but also a memorable personal experience.

We are excited to host you in this beautiful corner of Malaysia and look forward to a conference filled with learning, collaboration, and inspiration.

Warm regards,

Dr Kamal Raj Perumal

Scientific Chairman, MUC 2025
34th Malaysian Urological Conference 2025



Message

FROM THE

President of the Malaysian Urological Association



Assalamualaikum, Salam Sejahtera, Salam Malaysia Madani to everyone.

Welcome to the 34th Malaysian Urological Conference!

On behalf of the Malaysian Urological Association (MUA), it is both an honor and a pleasure to welcome our esteemed members, invited guests, and delegates to SPICE Penang, Malaysia, for the 34th Malaysian Urological Conference (MUC) 2025. This year's theme, "Innovating Urology Inspiring Care," reflects the rapid advancements in technology that are transforming the field of urology.

I extend my gratitude to our Organizing Chairmen, Dr. Aaron Goh Yue Keng, along with our Scientific Chair, Dr. Kamal Raj Perumal, for curating an exceptional program centered on this theme. I would like to thank our conference advisor, Dr. Clarence Lei, Teh Guan Chou, Dr. Lim Meng Shi, Dr. Khor Tze Wei and Dr. Chan Siew Hong, for their invaluable guidance and support. The dedication, along with the efforts of the entire organizing team, has made this event possible.

We are truly privileged to host distinguished speakers from globally renowned urological associations, including BJUI, EAU, UAA, USANZ, SIU, FAUA, USI, and NAUS. Their presence and experience will strengthen international collaborations and inspire new connections. We are pleased to have representatives from various international organizations join us at MUC 2025. Your participation enriches our gathering, and we are grateful for your commitment.

A special note of thanks goes to our local and international speakers, whose insights and contributions will enhance the value and prestige of this conference. Our program has consistently attracted a significant number of nursing professionals, who play an important role in delivering high-quality urological care. Hence, I extend my appreciation to AUSTEG and AUNA for their essential contributions to the nursing symposium.

Beyond the scientific program, I hope all our invited speakers and delegates will also take the opportunity to enjoy the unique cultural heritage that Kuching Sarawak has to offer.

Finally, my sincere thanks go to our pharmaceutical and medical device industry partners for their generous support, which has been instrumental in making this conference a success.

Thank you and I wish you all a fruitful and enjoyable conference.

Dr. Noor Ashani bin Md. Yusoff

President,
Malaysian Urological Association (2024 - 2026)



For the time he deserves



For Rapid Response & Sustained Serum Testosterone Suppression In Prostate Cancer Management¹

The only LHRHa with
proven survival benefits
over 10 years^{2,3}



Well characterized safety
profile established over
30 years of clinical practice^{4,5}

1 and only LHRHa with
SafeSystem & ready to use^{4,5}



2 dosing formulations:
monthly & trimonthly which
allows flexibility

REFERENCES

1. Fernandez del Moral P et al. Urology. 1996; 48(6):894-900. 2. Carrie C et al. Lancet Oncol. [Epub ahead of print October 16, 2019] 3. Bolla M et al. Lancet Oncol. 2010;11:1066-73. 4. ZOLADEX (goserelin acetate implant) 3.6 mg. Prescribing Information V7, June 2022. 5. ZOLADEX (goserelin acetate implant) 10.8 mg. Prescribing Information V9, August 2024.

Zoladex[®]
goserelin



ORGANISING COMMITTEE

Advisor	Clarence Lei Chang Moh Teh Guan Chou Lim Meng Shi Khor Tze Wei Chan Siew Hong
Chairman	Aaron Goh Yue Keng
Scientific Program Chair	Kamal Raj Perumal (Scientific Chairperson) Ng Ing Soon (Co-Scientific Chairperson)
Abstract Committee Chair & Publicity	Ahmad Nazran Fadzli Jeffery Wong Thiban
Nursing Program Chair	Kamalraj A/L Perumal Mohd Azzuddin Bin Abidin
Social Chair	Michelle Eng Mi-Lin Fung Hwa Jiang
Semi Live Surgery Workshop	Ngu Ing Soon
Endourology Night	Git Kah Ann Chew Tien Chuen Edmund Suryah

MALAYSIAN UROLOGICAL ASSOCIATION EXECUTIVE COMMITTEE (2024 – 2026)

President	Noor Ashani Md Yusoff
Vice President	Shanggar Kuppusamy
Hon Secretary	Vijayan Manogran
Hon Treasurer	Toh Charng Chee
Committee members	Goh Yu Keng William Ong Lay Keat Suriaraj Karppaya



Innovating Urology
INSPIRING CARE



Local Faculty



Malaysia

Cathryn Tai Shao Ni
Ch'ng Ling Sing
Chew Tien Chuen
Clarence Lei
Criss Low Yann Ling
Fam Xeng Inn
Git Kah Ann

Kamalraj Perumal
Lee Yi Wen
Lo Hwa Loon
Nalina Devi Selvakumar
Noor Ashani Md Yusoff
Norbaiti Seae
Nur Azren Abdul Aziz
Rohan Malek

Surya Lemin
Tan Guan Hee
Toh Charng Chee
Uma Devi Ramadass
Voon Hian Yan
Wong Peng Shyan
Yap Yok Chin

Invited Faculty



Australia

Lewis Chan Wen Loon
Marinelle DOCTOR
Marlon Perera
Weranga Ranasinghe
Yap Hin Wai



China

Kai Zhang
Wang He



France

Thomas Blanc



Greece

Athanasios Papatsoris



India

Tarun Jindal



Indonesia

Moh. Ayodhia Soebadi



Japan

Shuji Isotani
Takafumi Yanagisawa
Takaaki Inoue



Korea

John Jang Hwa Kim



Nepal

Suman Chapagain



Philippines

Arturo P. Castro, Jr



Singapore

Benjamin Goh Yen Seow
Henry Ho Sun Sien
Kwok Jia-Lun
Tiong Ho Yee



Taiwan

Jacob ST Pang



Thailand

Passakorn Amnattrakul
Tanet Thaidumrong



United Arab Emirates

Mohamad Fakih



United Kingdom

Asif Muneer
Christopher Eden
Grenville Oades



United States of America

Leonard G Gomelia

PRE-CONGRESS SEMI-LIVE SURGERY

Thursday 20 November 2025 | Pullman Hotel Kuching

COLOSSEUM 1 ROBOTIC SYMPOSIUM		TAJ MAHAL ENDOUROLOGY SYMPOSIUM
0830 REGISTRATION		
0855 WELCOME AND OVERVIEW		
0900 – 1230 PROSTATECTOMY SESSION <i>Moderators:</i> Clarence Lei Chang Moh (Malaysia); Loh Chit Sin (Malaysia) <i>Panelists:</i> Noor Ashani Md Yusoff, (Malaysia); Christopher Eden, (United Kingdom); Tanet Thaidumrong, (Thailand); Marlon Perera, (Australia); Jacob ST Pang, (Taiwan)	Moderated Open Discussions : Before the First Cut • The Role of PSMA in Surgical Staging and Planning • Transperineal versus Transrectal Biopsy • Prostatectomy after Focal Therapy • Fine-tuning Port Placement in Prostatectomy	1000 – 1100 Breakout Session: Closing the Gap in RIRS Safety: Real-Time IRP Monitoring with Tidor Intelligent Pressure- Control System <i>Speaker:</i> Banghua Liao (China) Pro Element Technology C Hugemed (Limited to 20 pax)
	Semi-Live Prostatectomy: 30-minute video by each panellist demonstrating a full case of moderate complexity with on-stage narration	
	Learning Points: • Nerve-Sparing Nuances Identification and Protection of the Neurovascular Bundle • Trouble at the Neck Dealing with Median Lobes and Preserving Bladder Neck • Leak Proof Success Apical dissection, Anastomosis Tips and Tricks, Reconstruction C Continence Preservation • Braving the Battlefield Surgery in Obese Patients, or Salvage Settings	
	Q&A Session	
1230 - 1330 LUNCH SYMPOSIUM BY DEVICE TECHNOLOGIES Evolving into a Total Robotic Urologist: Application on DV across all Urology Procedures, C Use of Confocal Microscopy in My Practice <i>Speaker:</i> Marlon Perera (Australia) <i>Moderator:</i> Loh Chit Sin, (Malaysia)		1115 – 1215 Breakout Session: REZUM WATER VAPOUR THERAPY MASTERCLASS Boston Scientific (Limited to 20 pax)
1330 – 1700 PARTIAL NEPHRECTOMY SESSION <i>Moderators:</i> Teh Guan Chou (Malaysia) Murali Sundram (Malaysia) <i>Panelists:</i> Fam Xeng Inn (Malaysia); Warren Lo Hwa Loon (Malaysia); Tiong Ho Yee (Singapore); Henry Ho Sun Sien (Singapore)	Moderated Open Discussions : The Prep Before The Knife • Weighing Role of Preoperative Biopsy • Role of RENAL/PADUA Scores: Are They Still Relevant in Planning? • Transperitoneal vs Retroperitoneal Approach: How do we choose? • Oncological Safety of Tumour Enucleation • Port Placements in Transperitoneal and Retroperitoneal Approaches	1330 – 1530 Breakout Session: RIRS MASTERCLASS Hands-on session with surgical models Evomedic C Macrolux (Limited to 20 pax)
	Semi-Live Partial Nephrectomy: 30-minute video by each panellist demonstrating a full case of moderate complexity with on-stage narration	
	The Buried Truth: Endophytic Tumours Henry Ho Sun Sien (Singapore)	
	Between Vessels: Hilar Tumours Warren Lo Hwa Loon (Malaysia)	
	The Flip Side: Posterior Tumours Tiong Ho Yee (Singapore)	
	Supersized Challenges: Multiple or Large Tumours Fam Xeng Inn (Malaysia)	
Q&A Session		
1700 FINAL COMMENTS AND CLOSING		
1900 – 2200 ENDUROLOGY NIGHT BY SURGIMEDIC		

PRE-CONGRESS SEMI-LIVE SURGERY: NURSES' ROBOTIC SYMPOSIUM

Thursday 20 November 2025 | Colosseum 2, Pullman Kuching Sarawak

TIME	Event / Topic	Speaker
0800 – 0850	Registration	
0850 – 0900	Welcome and Overview	
0900 – 1030 KEYNOTE LECTURES	Decoding the Da Vinci: Mastering Robotic Components and Functions	Criss Low Yann Ling, <i>Malaysia</i>
	Partners in Precision: Elevating Nursing Practice in Robotic Surgery	Nalina Devi Selvakumar, <i>Malaysia</i>
	Orchestrating Excellence: Robotic Surgery Setup for the Nursing Team	Lee Yi Wen, <i>Malaysia</i>
	Q & A	
1030 – 1200 TECHNICAL LECTURES	The Perfect Dock: Mastering Setup and Positioning of the Da Vinci System	Cathryn Tai Shao Ni, <i>Malaysia</i>
	Seconds Matter: Efficient Instrument Exchange and Robotic Error Management	Cathryn Tai Shao Ni, <i>Malaysia</i>
	The Real OR Experience: Overcoming Robotic Surgery Challenges	Noorbaiti Binti Seae, <i>Malaysia</i>
	Q & A	
1230 - 1300	Lunch Symposium by DTG Medical Sdn Bhd	
	Evolving into a Total Robotic Urologist: Application on DV across all Urology Procedures, & Use of Confocal Microscopy in My Practice Speaker : Marlon Perera, <i>Australia</i> Moderator : Loh Chit Sin, <i>Malaysia</i>	
1330 – 1700 HANDS ON SESSION	From Set-up to Assisting A Hands-on Da Vinci Skills Lab	Trainers Sarawak General Hospital, Malaysia Device Technologies, Malaysia, Thailand Private Sector, Malaysia



PUSH BACK EARLY. EXTEND LIFE.¹⁻³



ERLEADA[®] is indicated:¹

- in adult men for the treatment of non-metastatic castration-resistant prostate cancer (nmCRPC) who are at high risk of developing metastatic disease
- in adult men for the treatment of metastatic hormone-sensitive prostate cancer (mHSPC) in combination with androgen deprivation therapy (ADT)

Reference:

1. ERLEADA[®] Approved Prescribing Information Malaysia. 2. Chi KN, et al. J Clin Oncol 2021;39:2294-2303. 3. Chi KN, et al. N Engl J Med 2019;381:13-24.

Johnson & Johnson

For Healthcare Professionals only.
Further information is available upon request.

Johnson & Johnson Sdn Bhd (Co. No. 3718-D)
Level 8, The Pinnacle, Persiaran Lagoon, Bandar Sunway, 46150
Petaling Jaya, Selangor Darul Ehsan, Malaysia.
Tel: +603 7661 4500 Fax: +603 7610 0519
© 2025 Johnson & Johnson Sdn. Bhd. All rights reserved. Creation
Number: CP-543587 • Creation Date: September 2025 This
material is valid for one year from creation date.

 **Erleada[®]**
(apalutamide) tablets

**For the full Erleada[®] prescribing
information, please scan the QR code.**



This is real. This is efficacy in action.^{1*}

Omar is a grandpa, bill
payer, entrepreneur and
prostate cancer warrior.

Uncomfortable and in need of
support, patients with prostate cancer
deserve treatment decisions based on
trusted therapies.²⁻⁷

With over ten years' real-world
evidence of helping real men face
prostate cancer, Diphereline® has the
experience to understand what
matters most to them.^{1,3,4,8,9}

 **Diphereline®**
triptorelin

THE BACKBONE THERAPY THAT UNDERSTANDS TODAY'S MAN LIVING WITH PCa

*Data from a real-world cohort of 3,411 patients who were treated with Diphereline® only (1,326; 38.9%) or Diphereline® combined with an anti-androgen (2,085; 61.1%). Patients were included if they had ≥1 prescription of Diphereline® between 2015 and 2020 and had no evidence of metastasis. Follow-up continued until 2021. There were 847 deaths and 1,037 patients had a treatment switch during follow-up. The median observed median duration of treatment were not reached in both groups.



Before prescribing, please refer to the full
prescribing information, which is available
via scanning this QR code.

PCa, prostate cancer.

References: 1. Caffo O, et al. *Glob Reg Health Technol Assess.* 2024;11:207-213. 2. Pérez-López A, et al. *Pharmacoeconomics.* 2020;12(11):1028. 3. Diphereline® Malaysia Diphereline PR 3.75 mg Package Insert (Date of revision: Jun 2024). 4. Malaysia Diphereline PR 11.25 mg Package Insert (Date of revision: May 2024). 5. Heyns CF, et al. *BJU Int.* 2003;92(3):226-231. 6. Shim M, et al. *Investig Clin Urol.* 2019;60:244-250. 7. Klotz L, Tai T. *BJU J Compass.* 2024;5(3):392-402. 8. Gil T, et al. *Ther Adv Urol.* 2015;7(3):116-124. 9. Gil T, et al. *Ther Adv Urol.* 2017;9(7):179-190.

DIP-MY-000450 | October 2025

FOR HEALTHCARE PROFESSIONAL USE ONLY

All adverse events should be reported to ZPMYPV@zueligpharma.com

FRIDAY, 21 NOVEMBER 2025

COLLOSEUM 1, PULLMAN HOTEL, KUCHING



TIME	Event / Topic	Speaker
0700 – 0800	Registration	
PLENARY 1: BLADDER CANCER Moderators: Teh Guan Chou (Malaysia), Khoo Hau Chun (Malaysia)		
0800 – 0815	UAA LECTURE: En-Bloc Resection of Bladder Tumour- What's New Beyond the Horizon?	Takafumi Yanagisawa, Japan
0815 – 0830	CUA LECTURE: Tips and Tricks in Cystectomy and Innovative Techniques in Neobladder Surgery	Wang He, China
0830 – 0845	Beyond White Light: Is Enhanced Cystoscopy the New Standard?	Kamalraj Perumal, Malaysia
0845 – 0900	Beyond BCG – Emerging Therapies for High Risk NMIBC	Lim Teck Onn, Malaysia
0900 – 0915	Panel Discussions	
0915 – 0945	MORNING TEA SYMPOSIUM by AstraZeneca Sdn Bhd Beyond Surgery & Chemotherapy HOW IMMUNOTHERAPY IS TRANSFORMING MIBC CARE Chairperson : Ong Teng Aik, <i>Malaysia</i> Speaker : Jacob See-Tong Pang, <i>Taiwan</i>	
0945 – 1015	OPENING CEREMONY	
1015 – 1045	EXHIBITION VISIT AND TEA BREAK	
PLENARY 2: UROLITHIASIS & INFECTIONS Moderators: Khor Tze Wei (Malaysia), William Ong Lay Keat (Malaysia)		
1045 – 1100	VIRTUAL JUA LECTURE: Innovations in Stone Surgery – Are we at the Peak or Just Getting Started?	Takaki Inoue, Japan
1100 – 1115	Laser Performance: Concepts in the Era of Advanced Lasers, Suction and FANS	Kwok Jia-Lun, Singapore
1115 – 1130	Antibiotic stewardship in Urology. Navigating Resistance in Era of Overuse	Wong Peng Shyan, Malaysia
1130 – 1145	MEGA: Make ESWL Great Again	Git Kah Ann, Malaysia
1145 – 1200	Panel Discussions	
PLENARY 3: PENILE AND TESTICULAR CANCER Moderators: Lim Meng Shi (Malaysia), Kumarappan Alagappan (Malaysia)		
1200 – 1215	The Role of Robotic and Minimally Invasive Surgery in Testicular Cancer – The Malaysian Experience	Noor Ashani Md Yusoff, Malaysia
1215 – 1230	NAUS LECTURE: From Concept to Clinic: Validating a microRNA-Based Liquid Biopsy Algorithm for Testicular Germ Cell Tumors	Suman Chapagain, Nepal
1230 – 1245	USI LECTURE: Evolving Standards: Can Minimally Invasive Inguinal LND Replace Open?	Tarun Jindal, India
1245 – 1300	Panel Discussions	
1300 - 1400	LUNCH SYMPOSIUM by Ipsen Pharma Singapore Ltd Pte ADT IN PCA: CLINICAL RELEVANCE & EVOLVING PERSPECTIVE Chairperson : Shanggar Kuppusamy, <i>Malaysia</i> Speaker : Lo Hwa Loon, <i>Malaysia</i>	





TIME	Event / Topic	Speaker
PLENARY 4: PAEDIATRIC UROLOGY Moderators: Susan Woo Yoke Yin (Malaysia), Kamalraj Perumal (Malaysia)		
1400 – 1415	LIVE LECTURE: Robotic Paediatric Urology: A Decade of Experience at Hospital Necker Enfants- Malades	Thomas Blanc, France
1415 – 1430	The Future of Foetal Urology – Innovations in Prenatal Diagnosis and Intervention	Voon Hian Yan, Malaysia
1430 – 1445	Challenges of Managing CKD in Adolescent Patients	Yap Yok Chin, Malaysia
1445 – 1500	Paediatric Urology in Malaysia: Overcoming Challenges & Transition of Care	Clarence Lei Chang Moh, Malaysia
1500 – 1515	Case Based Discussion in Paediatric Urology	Ch'ng Ling Sing, Malaysia
1515 – 1545	AFTERNOON SATELLITE SYMPOSIUM by Astellas Pharma (M) Sdn Bhd “Embarking on the journey in nmHSPC” Moderator : Lim Meng Shi Speaker : Henry Woo	
PLENARY 5: FUNCTIONAL AND RECONSTRUCTIVE UROLOGY Moderators: Chan Siew Hong (Malaysia), Samuel Tan Yon Xiang (Malaysia)		
1545 – 1600	FAUA-InaNUA LECTURE: Urethral Stricture Managements – Moving Beyond Traditional Techniques	Moh. Ayodhia Soebadi, Indonesia
1600 – 1615	Robotic Surgery in Functional and Reconstructive Urological Surgery: Is it the Way Forward?	Warren Lo Hwa Loon, Malaysia
1615 – 1630	Endopelvic Ultrasound: Should it be a Routine Practice for Assessment of Female Urological Problems Nowadays?	Lewis Chan Wen Loong, Australia
1630 – 1645	KUA LECTURE: Emerging Therapy in the Management of Underactive Bladder	John Jang Hwan Kim, South Korea
1645 – 1700	Panel Discussion	
1700 – 1730	EXHIBITION VISIT AND TEA BREAK	
1730 – 1930	MUA ANNUAL GENERAL MEETING	



SATURDAY, 22 NOVEMBER 2025

COLLOSEUM 1, PULLMAN HOTEL, KUCHING



TIME	Event / Topic	Speaker
0800 – 0830	Breakfast Symposium by Johnson & Johnson Sdn Bhd Advancing mCSPC care: Integrating Real-World Case Studies and Emerging Treatment Paradigm Speaker : Loh Chit Sin	
PLENARY 6: RENAL CANCER Moderators: Fam Xeng Inn (Malaysia), Mohd Najib Aziz (Malaysia)		
0830 – 0845	Diagnostic Precision or Procedural Delay? The Renal Biopsy Dilemma	Grenville Oades , <i>United Kingdom</i>
0845 – 0900	FAUA-TUA LECTURE: The Role of Active Surveillance for Small Renal Cancers. Are we Overtreating?	Passakorn Amnattrakul , <i>Thailand</i>
0900 – 0915	Robotic Partial Nephrectomy - How Far Can We Push It?	Henry Ho Sun Sien , <i>Singapore</i>
0915 – 0930	SIU LECTURE: Cytoreductive Nephrectomy in Metastatic RCC – Still Relevant in the Immunotherapy Era?	Athanasios Papatsoris , <i>Greece</i>
0930 – 0945	Efficacy of Robotic Partial Nephrectomy in Complex Tumours – The Malaysian Perspective	Fam Xeng Inn , <i>Malaysia</i>
0945 – 1000	Panel Discussions	
1000 – 1030	MORNING TEA SYMPOSIUM by GSK Breaking barriers in Benign Prostatic Hyperplasia(BPH) Treatment Chairperson : Clarence Lei Speaker : Rohan Malek	
1030 – 1100	EXHIBITION VISIT AND TEA BREAK	
PLENARY 7: BPH AND ANDROLOGY Moderators: Chai Chu Ann (Malaysia), Uma Dhevan (Malaysia)		
1100 – 1115	FAUA-PUA LECTURE: BPH Treatments Past Conventional TURP: LASER Resection of the Prostate (ThuLEP C HoLEP):	Arturo P. Castro, Jr , <i>Philippines</i>
1115 – 1130	Varicocele Repair for Male Infertility – Necessary or Overused?	Asif Muneer , <i>United Kingdom</i>
1130 – 1145	The Future of ED Treatment; Penile Prosthesis vs Regenerative Therapy	Asif Muneer , <i>United Kingdom</i>
1145 – 1200	Panel Discussions	
PLENARY 8: PROSTATE CANCER Moderators: Teh Guan Chou (Malaysia), Loh Chit Sin (Malaysia)		
1200 – 1215	BJUI LECTURE: AI in Prostate Cancer Care – Hype or Real Progress?	Weranja Ranasinghe , <i>Australia</i>
1215 – 1230	MRI-targeted vs Systematic Biopsies: Should we Eliminate Random Biopsies?	Tan Guan Hee , <i>Malaysia</i>
1230 – 1245	EAU LECTURE: Future of Minimally Invasive Surgery in Prostate Cancer: Robotics and Beyond	Christopher Eden , <i>United Kingdom</i>
1245 – 1300	Precision Medicine in Advanced Prostate Cancer	Leonard G Gomella , <i>United States</i>
1300 – 1315	Panel Discussion	
1315 – 1400	LUNCH SYMPOSIUM by Eisai (M) Sdn Bhd Setting New Benchmark in Efficacy and Safety : Introducing BEOVA (VIBEGRON) : A Novel Selective Beta – 3 Receptor Agonist Chairperson : Clarence Lei Speaker : Teh Guan Chou	



SATURDAY, 22 NOVEMBER 2025

COLLOSEUM 1, PULLMAN HOTEL, KUCHING



TIME	Event / Topic	Speaker
PLENARY 9: KIDNEY TRANSPLANTATION Moderators: Vijayan Manogran (Malaysia), Durvesh Jethwani (Malaysia)		
1400 – 1415	Kidney Transplantation in Obese Patients: Breaking Barriers or Increasing Risks	Toh Charng Chee , <i>Malaysia</i>
1415 – 1430	FAUA-SUA LECTURE: The Role of Minimally Invasive Surgery in Kidney Transplantation: A Game Changer or a Niche Technique?	Benjamin Goh Yen Seow , <i>Singapore</i>
1430 – 1445	Factors Determining Which Kidney to Take in Living Related Renal Transplant: How Does a Surgeon Decide?	Rohan Malek , <i>Malaysia</i>
1445 – 1500	MSN LECTURE: Precision Immunosuppression in Kidney Transplantation: Are we Ready for a Personalized Approach?	Mohamad Zaimi Abdul Wahab , <i>Malaysia</i>
1500 – 1515	Panel Discussion	
1515 – 1545	AFTERNOON TEA SYMPOSIUM by Easmed, Thulio official launch in Malaysia	
PLENARY 10: PROFESSIONAL PRACTICE IN UROLOGY Moderators: Clarence Lei Chang Moh (Malaysia), Ngu Ing Soon (Malaysia)		
1545 – 1600	Transitioning from Resident to Consultant	Yap Hin Wai , <i>Australia</i>
1600 – 1615	Urological Training Opportunities in Australia	Yap Hin Wai , <i>Australia</i>
1615 – 1630	Urological Training Opportunities in the UK	Asif Muneer , <i>United Kingdom</i>
1630 – 1645	Urological Training Opportunities in the United States	Leonard G Gomella , <i>United States</i>
1645 – 1700	Panel Discussion	
1700 – 1730	EXHIBITION VISIT AND TEA BREAK	
1730 – 1930	MUC2025 GALA DINNER AND PRIZE PRESENTATION CEREMONY	



UROLOGY NURSING SYMPOSIUM

FRIDAY 21 November 2025

Colosseum 2, Pullman Kuching Sarawak

AUNA SESSION: NURSING ROLE IN UROONCOLOGY Moderators: Ch'ng Ling Sing (Malaysia); Muhammad Ngu Ing Soon (Malaysia)		
0815 – 0830	Introduction to AUNA	Mohamad Fakh, <i>United Arab Emirates</i>
0830 – 0845	Fast-Tracking Recovery: ERAS in Urological Oncology	Marinelle Doctor, <i>Australia</i>
0845 – 0900	Nursing in Uro-Oncology: Bridging Care with Compassion and Innovation	Marinelle Doctor, <i>Australia</i>
0900 – 0915	Panel Discussion	

0915 – 0945	Morning Tea Symposium by AstraZeneca Sdn Bhd Surgery and Chemotherapy – How Immunotherapy is Transforming MIBC Care Moderator : Ong Teng Aik, <i>Malaysia</i> Speaker : Jacob See-To Pang, <i>Taiwan</i>	
-------------	---	--

0945 – 1015	Opening Ceremony	
1015 – 1045	EXHIBITION VISIT AND TEA BREAK	

AUNA SESSION: NURSING ROLE IN UROONCOLOGY Moderators: Ch'ng Ling Sing (Malaysia); Muhammad Ngu Ing Soon (Malaysia)		
1100 – 1115	Artificial Intelligence in Urology: How Nurses Can Adapt and Benefit	Mohamad Fakh, <i>United Arab Emirates</i>
1115 – 1130	Maintaining Cold Ischemia Time: Best Practices for Organ Preservation in Renal Transplantation	Nur Azren Abdul Aziz, <i>Malaysia</i>
1130 – 1145	Practical Insights: Challenges and Success Stories in Transplant – Interactive session	Uma Devi Ramadass, <i>Malaysia</i>
1145 – 1200	Panel Discussion	

AUSTEG SESSION: UROLITHIASIS AND ENDOUROLOGY Moderators: Chang Bing Chi (Malaysia); Umadhevan Kanapathy (Malaysia)		
1200 – 1215	Introduction to AUSTEG	Shuji Isotani, <i>Japan</i>
1215 – 1230	VIRTUAL LECTURE: Challenges and Solutions in Complex Stone Cases	Takaaki Inoue, <i>Japan</i>
1230 – 1245	New Frontiers in Stone Disease Management: Laser Lithotripsy and Beyond	Kai Zhang, <i>China</i>
1245 – 1300	Panel Discussion	

1300 - 1400	Lunch Symposium by Astellas Pharma (M) Sdn Bhd ADT in PCA: Clinical Relevance & Evolving Perspective Moderator : Shanggar Kuppusamy, <i>Malaysia</i> Speaker : Warren Lo Hwa Loon, <i>Malaysia</i>	
-------------	---	--

AUSTEG SESSION: ENDOUROLOGY HANDS-ON SESSION Moderators: Nurul Zubidah Bt Shahul Hameed (Malaysia); Mugilan Pushpanathan (Malaysia)		
1400 – 1415	Overview of Endourology & the Nurse's Role	Shuji Isotani, <i>Japan</i>
1415 – 1430	Hydration, Diet, and Medications: A Nurse's Guide to Preventing Recurrent Kidney Stones	Surya Binti Lemin, <i>Malaysia</i>
1430 – 1445	Best practices for instrument handling, sterilization, and radiation safety	Chew Tien Chuen, <i>Malaysia</i>
1445 – 1500	Panel discussion	

AUSTEG SESSION: ENDOUROLOGY HANDS-ON SESSION		
1500 – 1700	Hands-on Session	Certified Nurse Trainers Sarawak General Hospital, Malaysia Olympus Malaysia, Malaysia


Simply see more.



Discover Next Generation, Patient-centered Diagnostic imaging with the VISERA™ S Video System

With a built-in LED light source that is designed for improved color, resolution, and depth of field, the compact VISERA S system provides a clear view of fine vascular structures.*


Enhanced cystoscopy is a more powerful way to visualize bladder cancer than using traditional White Light Imaging (WLI) alone. Narrow Band Imaging™ (NBI™) technology is included with all Olympus® video systems and has led to 37%** less likelihood of recurrence over 12-35 months.¹



Traditional WLI



NBI technology



Visit Booth #648 to learn more about Olympus' latest innovations

The VISERA S video system is a compact, integrated office and ambulatory diagnosis system designed for endoscopic diagnosis, treatment, and video observation. The endoscope connected to this video system center must never be applied directly to the heart because leakage current from the TYPE BF applied part may cause ventricular fibrillation or otherwise seriously affect the cardiac function of the patient.

Based on a weighted average, studies have shown that using NBI technology allows physicians to visualize lesion boundaries. NBI technology is not intended to replace histopathological sampling as a means of diagnosis.

* When compared to CV-170 video system and OTV-S7H-N. Data on file (DC00835040, DC00835041) N=7 Urologists.

** Derived from the hazard ratio in the study. Low certainty of evidence due to risk of bias and imprecision.

1. Lai LY, Tafuri SM, Ginier EC, Herrel LA, Dahm P, Maisch P, Lane GI. Narrow band imaging versus white light cystoscopy alone for transurethral resection of non-muscle invasive bladder cancer. Cochrane Database of Systematic Reviews 2022, Issue 4. Art. No.: CD014887. DOI: 10.1002/14651858.CD014887.pub2.

2. Li, K., Lin, T., Fan, X., Duan, Y., & Huang, J. (2013). Diagnosis of narrow-band imaging in non-muscle-invasive bladder cancer: A systematic review and meta-analysis. International Journal of Urology, 20, 602-609. www.ncbi.nlm.nih.gov/pubmed/23113702



MALAYSIA

**Cathryn Tai Shao Ni**

Product Specialist - da Vinci Surgery
Device Technologies

Since 2023, I have worked at the forefront of surgical innovation as a Clinical Product Specialist with Device Technologies, specialising in da Vinci robotic-assisted surgery. In this role, I conduct in-theatre training and case support for surgeons and perioperative teams, helping them progress through their da Vinci learning curves efficiently and safely. I lead tailored educational programs for both surgeons and operating room staff, ensuring comprehensive understanding and confident use of the technology across various specialties.

My core focus is to support case series completion through hands-on guidance, clinical insights, and real-time troubleshooting. I work closely with multidisciplinary teams to optimize patient outcomes through effective technology adoption and workflow integration.

With a strong commitment to advancing surgical excellence, I bring a patient-centered approach, in-depth knowledge of robotic systems, and a collaborative mindset to every engagement.

**Ch'ng Ling Sing**

General Urologist, Hospital Sultan Idris Shah (Serdang, Malaysia)

Dr Ch'ng Ling Sing is a General Urologist at Hospital Sultan Idris Shah (HSIS). She graduated with an MBBS and Bachelor of Medical Science from the University of Melbourne in 2012, and completed the Malaysia Urology Parallel Pathway in 2023.

Her current clinical practice focuses on urological oncology, stone disease, and other general urology work, while maintaining an ongoing interest in paediatric urology.

**Chew Tien Chuen**

Dr Chew obtained his Bachelor of Medicine and Bachelor of Surgery (MBBS) from Manipal Academy of Higher Education in 2015 and subsequently earned his Membership of the Royal College of Surgeons of Edinburgh (MRCSEd) in 2022. He is currently a third-year Urology Trainee at Hospital Umum Sarawak. His clinical interests focus on minimally invasive oncology and endourological surgery, particularly in the management of urinary stone disease and the development of radiation-free surgical techniques.

**Clarence Lei Chang Moh**

Consultant Urologist
Normah Medical Specialist Centre, Kuching

Dr Clarence Lei Chang Moh is consultant urologist at the Normah Medical Specialist Centre in Kuching and adjunct professor of Universiti Malaysia Sarawak. He is honorary consultant to Sarawak General Hospital & HKL. He qualified from University of Malaya in 1981 and obtained his Fellowship with the Royal College of Surgeons & Physicians of Glasgow in 1986. He subsequently trained in GHKL, University College London, GOS, Great Ormond Street Children for Sick Children, London and Edinburgh Western GH and Nuffield Transplantation Surgical Unit NTSU. He obtained his FRCS Urology and FEBU (Fellow of European Board of Urology). He was urologist at the General Hospital in KL till 1994. He was head of surgery at Universiti Malaysia Sarawak 1995 – 1998. He is a past President of the Malaysian Urological Association, an examiner of the Royal Colleges of Edinburgh and Glasgow & Malaysian Board of Urology. His special interests include paediatric urology, renal transplantation, surgery for renal failure, urinary stone disease, men's health and medical education.

**Criss Low Yann Ling**

Field Sales Manager
DTG Medical

Experienced medical device professional with over 10 years in the healthcare and medical technology industry. Skilled in product management, clinical training, and surgical support. Proven success in training surgeons and healthcare teams in the use of advanced robotic systems. Currently pursuing an MBA to enhance leadership and strategic management capabilities.



**Fam Xeng Inn**

Associate Professor and Consultant
Urology in Faculty of Medicine, UKM

He attained his Degree of Doctor of Medicine (MD) and Master Degree of Doctor of General Surgery (Dr Gen Surg) from Universiti Kebangsaan Malaysia (UKM). He subspecialized in Urology and was awarded with Urology Fellowship by Royal of Physicians and Surgeons of Glasgrow FRCS (Urol) (Glasg). He is a certified urologist by Malaysian Board of Urology (MBU).

He completed his fellowship of Laparoscopic and Robotic Urology Surgery in Urology Department, Chinese People Liberation Army General Hospital, Beijing China. He is a certified console surgeon for da Vinci Robotic Surgical System.

Dr Fam currently serve as the director for Special Interest Group of Minimal Invasive Surgery (Laparoscopic), Malaysia Urology Association. He is also steering faculty for Asia Urological Surgery Training and Education Group (AUSTEG).

He specializes and have vast experience in endourology, advanced laparoscopic and robotic urology surgery

**Git Kah Ann**

Consultant Urologist
Pantai Hospital Penang

Dr. Git Kah Ann is a Consultant Urologist at Pantai Hospital Penang. He graduated from University of Malaya, Kuala Lumpur in 1996 and obtained his Masters of Surgery from University Kebangsaan Malaysia in 2003 where he was the best candidate in the Masters Examination. He is a Malaysian Board Certified Urologist from 2008 and conferred the FRCS(Urol) of Glasgow. He spent a year on Melbourne, Australia (2008-2009) as a Clinical Fellow in Urology. He is also an academician in the Academy of Medicine Malaysia. Despite currently in private practice he has a keen interest in teaching and is a former Board Member of the Malaysian Board of Urology and appointed Honorary Consultant Urologist to the Department of Urology of Hospital Pulau Pinang. He is also an Organising Committee Advisor and Faculty of the Malaysian Urological Conferences and a faculty at the Malaysian Advanced Urology Courses. Since 2011, Dr. Git have organised and moderated the Endourology Night at the Malaysian Urological Conferences. He started the Penang Stone Course in 2010 and is now a popular Urology course in Malaysia. He has organised and performed several live workshops in Endourology both locally and abroad. With his keen interest, he is currently the Director of Endourology of the Malaysian Urological Association.

**Kamalraj Perumal**

Urologist, Sarawak General Hospital,
Sarawak, Malaysia

Graduated from UCSI University, Malaysia in the year 2013, then completed FRCS(Urol) Glasgow and Malaysia Board of Urology certification in November 2022.

Started his medical carrier as a House Officer in Selayang Hospital from 2013 to 2015, underwent 6 different rotation. Then, service as a Medical Officer in General Surgery Department in Bintulu Hospital since 2015 before joining Urology Department of Sarawak General Hospital in 2018.

A highly motivated, team orientated and compassionate Urologist with great interest in the field of Urology, especially in Paediatric Urology, Reconstructive Surgery, Endourology and Minimally Invasive Surgery.

**Lee Yi Wen**

Personal Assistant cum Scrub Nurse
Genealgas Kuala Lumpur

Accomplished Perioperative Nurse and Personal Assistant with over a decade of expertise in robotic and laparoscopic surgery. Proficient in surgical workflows, sterile techniques, and providing comprehensive clinical and administrative support for complex procedures. Holds advanced nursing qualifications, including specialization in neurosurgery. Dedicated to optimizing surgical efficiency and enhancing patient outcomes through effective multidisciplinary collaboration.



Lo Hwa Loon

Dr. Warren Lo Hwa Loon is a Malaysian urologist whose expertise spans urinary stones, urinary tract cancers, recurrent infections, and men's and women's urological health, with subspecialty strengths in female urology, neuro-reconstructive urology, and minimally invasive oncological surgery. He performs complex procedures such as robotic and laparoscopic cancer surgeries, artificial urinary sphincters, slings, penile implants, Botox injections for overactive bladder, and sacral neuromodulation—being the only Malaysian urologist offering bladder pacemaker procedures and the country's leading provider of Botox therapy for overactive bladder. Trained in Malaysia, the UK, the U.S., France, Australia, and China, he completed fellowships in neuro-reconstructive urology, female urology, robotic uro-oncology, functional robotic urology, and kidney transplantation, supported by the prestigious Tun Suffiah Foundation scholarship. A Europe-certified robotic surgeon and accredited national robotic surgery proctor, he trains both urologists and gynecologists in Malaysia. Dr. Lo is academically active with international publications, conference leadership, and principal investigator roles, contributes to educational textbooks, and serves as an examiner for the Malaysian Urological Board and Vice President of the Malaysian Continence Society.



Mohamad Zaimi ABDUL WAHAB

Consultant Nephrologist
Hospital Kuala Lumpur, Malaysia

Dr. Mohamad Zaimi graduated from the University of Malaya in 2000. He completed his Masters in Internal Medicine at University Kebangsaan Malaysia in 2009. Dr. Zaimi has been a key part of the Nephrology Department at Hospital Kuala Lumpur after completing his Nephrology Training with the Ministry of Health, Malaysia, in 2014. He is currently the head of the Transplantation Unit at Hospital Kuala Lumpur and has been with the unit since 2015. Dr. Zaimi also serves as a trainer for the 1st ODISSEA program (Organ Donation Innovative Strategies in South East Asia). Dr. Zaimi is actively involved in the Malaysian Kidney Allocation System (MyKAS) and has held several leadership positions within the Malaysian Society of Transplantation (MST). He was a council member from 2016 to 2018, served as treasurer from 2010 to 2022, was the vice president from 2022 to 2024, and has been elected as president for the term 2024 to 2026.



Nalina Devi Selvakumar

Nalina Devi Selvakumar is an accomplished Senior Staff Nurse with over 20 years of hands-on experience in the field of perioperative nursing. She holds a Bachelor's Degree in Nursing and a Post Basic qualification in Perioperative Nursing, which has built a strong foundation for her extensive clinical expertise and leadership in surgical care. Currently specialising in urology surgeries, Nalina has played a vital role in both living-related and cadaveric kidney transplant procedures. Her proficiency includes working with cutting-edge robotic technologies, particularly the Da Vinci robotic surgical system, where she supports complex minimally invasive procedures with skill and precision. Nalina is also passionate about nursing education and mentorship, serving as a local preceptor for Advanced Diploma in Perioperative Nursing students, guiding them through clinical training and surgical best practices. With a career defined by dedication, precision, and commitment to patient safety and education, Nalina brings a wealth of knowledge and practical insight to every platform she contributes to. It is an honor to welcome her as a speaker for this colloquium.

**Noor Ashani Md. Yusoff**

Senior Consultant Urologist and Head of Department
Hospital Kuala Lumpur, Malaysia.

Dr. Noor Ashani Md. Yusoff currently working as Senior Consultant Urologist and Head of Urology Department, Hospital Kuala Lumpur, Malaysia. He has been entrusted to be the Head of Urology Specialty in Ministry of Health Malaysia. He has been appointed as an Adjunct Professor at Hospital Sultan Azlan Shah UPM since year 2000. Currently he is also the President of Malaysia Urological Association (MUA). Recently he has been elected as a member of Malaysia Medical council.

He qualified as General Surgeon in 2002 after completed his Master of Surgery (General) at Universiti Kebangsaan Malaysia (UKM). He continue his training as Urologist under the auspice of Malaysia Board of Urology in collaboration with Ministry of Health Malaysia (MOH) and Malaysia Urological Association (MUA). And completed his urology training in 2007. He was conferred Diploma in Fellowship , FRCS (Urology)(Glasgow) in 2014.

His interest mainly in minimally invasive surgery particularly robotic assisted laparoscopic surgery and laparoscopic donor nephrectomy. He started his robotic surgery training in 2004 under the supervision by Dato' Dr. Sahabudin Raja Mohamed, the pioneer of robotic surgery in Malaysia. His robotic surgery training continue at Yonsei Severance Hospital, Seoul, Korea in 2010 under the supervision of Dr. Khoo Hon Rha, the pioneer of robotic surgery in Korea.

He has performed more than 500 cases of Robotic Assisted Laparoscopic surgery, from RAL Radical Prostatectomy to RAL Retroperitoneal Lymph Nodes Dissection. He is the pioneer RAL RPLND in Malaysia and has the largest series in South East Asia. He has proctored more than 100 cases of Robotic Assisted Laparoscopic Surgery throughout Malaysia and has been invited to give several talks related to Robotic Assisted Surgery local. or internationally.

**Noorbaiti binti Seae**

Senior Staff Nurse, Urology Operating Theatre, Hospital Kuala Lumpur

Experienced and dedicated Senior Staff Nurse with nearly 20 years of service in the Urology Operating Theatre at Hospital Kuala Lumpur. Holds a Diploma in Nursing and Post Basic in Perioperative Nursing. Specialized in Robotic Surgery, Urology Surgery, and Renal Transplant procedures. Committed to advancing perioperative nursing practice through continuous training, knowledge sharing, and excellence in patient care. Recognized speaker and trainer in robotic surgery both locally and internationally.

Work Experience

Senior Staff Nurse — Urology Operating Theatre, Hospital Kuala Lumpur (2005 – Present)

- Specialized nurse in robotic surgery since 2010.
- Skilled in urology and renal transplant surgical procedures since 2005 and 2008 respectively.
- Conducted multiple robotic training and hands-on sessions for nurses in the Urology OT.
- Served as local preceptor for Advanced Diploma in Perioperative Nursing students.
- Actively participated in international conferences and workshops on multispecialty robotic surgery.
- Ensure adherence to strict aseptic techniques, patient safety, and quality care standards.

**Nur Azren Abdul Aziz**

Hospital Selayang

Urology Operation Theatre, Hospital Kuala Lumpur
9 August 2010 - 6 September 2024
Hospital Selayang
September 2024 - current

EDUCATION

Kolej Sains Kesihatan Bersekutu, Johor Bahru, Johor — Diploma in Nursing

JULY 2007 - JULY 2010

Institut Latihan Kementerian Kesihatan Malaysia, Kuching Sarawak — Advanced Diploma in Perioperative Sub Urology

SEPTEMBER 2017 - SEPTEMBER 2018

SKILLS

Surgical patient care

Organ Procurement Surgery (kidney)

Renal Transplant Surgery Pediatric Urology Surgery Robotic Surgery Urodynamic Study

RESPONSIBILITIES

Educate and guiding graduate nurse on peri operative practice

Coordinate with specialist and staff to prepare for the surgery

Counter Nurse In-Charge for arranging Operating Room Surgeries, staff and OR schedule





Rohan Malek

Dato Dr Rohan Malek is presently a Consultant Urologist and Renal Transplant Surgeon at the Damansara 2 Specialist Hospital in Kuala Lumpur, Malaysia. He recently retired as the Head of Department of Urology, Selayang Hospital, Selangor and as the National Head for Urology, Ministry of Health, Malaysia. He served for 25 years as a Consultant Urologist in the government service. Dr Rohan Malek graduated from Monash University, Australia and initially underwent general surgical training and obtained his FRCS from RCS Edinburgh and RCPS Glasgow in 1993. He later underwent Urology specialty training at the Institute of Urology and Nephrology, Kuala Lumpur Hospital from 1993-1996 followed by a 1 year Fellowship in the United Kingdom. He obtained the Diploma in Urology from University College London in 1997 and is a Fellow of the European Board of Urology since 2004. His other major contributions included as Chairman of the Malaysian Board of Urology from 2008-2023, President of the Malaysian Urological Association (MUA) from 2004-2008. He was the organising Chairman for the 17th UAA Congress held in Kuala Lumpur in August 2019 and had been elected as the President of the Urological Association of Asia (UAA) from 2019-2020.



Surya Lemin

SN Surya is an experienced Operating Room Nurse with strong competencies in both scrub and recovery nursing. She has assisted in a wide range of surgical procedures, demonstrating excellent sterile technique, precise instrument handling, and effective teamwork with surgeons and anesthetists.

With over **7 years of experience in post-anesthesia recovery care**, she is skilled in monitoring patients, managing pain, and ensuring safe, smooth postoperative recovery. She is also proficient in handling high-pressure situations while maintaining patient safety and comfort as top priorities.

In addition to her **3 years of scrub nurse experience**, she possesses solid knowledge of perioperative workflows and patient safety practices. SN Surya also contributes to staff development as a **trainer for Basic Life Support (BLS) and Advanced Life Support (ALS) providers**.

Dedicated, organized, and continuously improving her skills, she is committed to delivering high-quality perioperative and postoperative care.



Tan Guan Hee

Prof. Dr. Tan Guan Hee is a Consultant Urologist in Sunway Medical Centre and Clinical Professor at Sunway University, Malaysia. He completed sub-specialty training under the Society of Urologic Oncology fellowship at the University of Toronto, Canada.

Prof. Tan has a keen interest in surgical technology. He is trained in minimally-invasive surgery and regularly performs robot-assisted operations, focusing on prostate and kidney cancers. He is an early adopter of novel technologies such as fusion transperineal biopsy of prostate and PSMA-based theranostics. His research interests are in smarter screening and early diagnosis for prostate cancer.



**Toh Charng Chee**

Dr. Toh Charng Chee is a Consultant Urologist and the Head of the Urology Department at Hospital Selayang. He obtained his Master of Surgery from the University of Malaya in 2012 and the FRCS (Glasgow) in Urology in 2016. Early in his career, he served as Head of the Surgical Department at Hospital Lahad Datu during the 2013 Lahad Datu standoff, for which he was awarded the Pingat Kedaulatan Negara by the Ministry of Health.

Currently, Dr. Toh leads Malaysia's renal transplant service at Hospital Selayang, the National Referral Centre. He has spearheaded strategic initiatives to train new kidney transplant surgeons, expand services to other states, and collaborate with private sector experts to strengthen the country's transplant capability. He also serves as an Exam Director on the Board of Urology, Treasurer of the Malaysian Urological Association, and is appointed as a Visiting Lecturer at the Faculty of Medicine, UiTM (General Surgery) as well as a Post-Basic Trainer for Paramedics.

At the hospital and cluster level, he contributes as a Member of MDAC and Urology Advisor for Klang Valley Cluster 1. He has also organized and led numerous international and national academic events, including the Malaysia Urology Conference (MUC 2023), the Art and Science of Renal Procurement workshop, multiple advanced surgical workshops (ECRIS, RIRS, TUERP), Paramedic Courses, and Medical Officer workshops.

A steadfast leader during both the Lahad Datu incursion and the COVID-19 pandemic, Dr. Toh is recognized as a vital asset to the urology fraternity in Malaysia. With a focus on renal transplantation—a field of strategic importance to the Ministry of Health—he continues to drive innovation, training, and service excellence at both national and international levels.

**Uma Devi Ramadass**

Ketua Koordinator Perolehan Organ & Tisu Negeri Sarawak
Sarawak General Hospital (Hospital Umum Sarawak), Ministry of Health Malaysia

Medical doctor with over 15 years of experience in anaesthesia, critical care, and organ and tissue procurement. Currently serving as the Ketua Koordinator Perolehan Organ & Tisu Negeri Sarawak, responsible for statewide and national coordination of deceased donation activities under the Ministry of Health Malaysia. Helped establish and operationalise Sarawak's first Organ and Tissue Procurement Unit at Hospital Umum Sarawak, reactivating donation activities after a nine year gap and achieving the first Indigenous (pribumi) organ donor in Sarawak General Hospital's history. Actively involved in MyGRODA training, CMEs, and public awareness initiatives. Holds an International Master in Donation and Transplantation of Organs, Tissues and Cells (University of Barcelona) and maintains active membership in the Malaysian Society of Transplantation and the European Society for Organ Transplantation.

**Voon Hian Yan**

Dr Voon is a Maternal-Fetal Medicine specialist who obtained his membership from the Royal College of Obstetricians & Gynaecologists in 2014 and subsequently underwent a 3-year fellowship in the Ministry of Health Malaysia and Royal Prince Alfred Hospital, Sydney. He is currently a consultant Maternal Fetal Medicine Specialist at one of the largest tertiary hospital in Malaysia, Sarawak General Hospital and an adjunct lecturer at Universiti Malaysia Sarawak.

He has been the Chairperson of the Ultrasound Committee of the Asia & Oceania Federation of Obstetrics & Gynaecology (AFOG) since 2022 and appointed to the Editorial Board of PREGNANCY the official journal of the Society for Maternal Fetal Medicine (SMFM). In addition, he is currently an elected council member of the Obstetrical & Gynaecological Society of Malaysia (OGSM), on its Scientific Committee and Editorial Board of the society's newsletter-CONNECT. He is also the State representative of the Perinatal Society of Malaysia (PSM).

In recognition of his contributions, Dr Voon was awarded the Shan S Ratnam Young Gynaecologist Award from AFOG in 2019 and is a recipient of the Excellent Service Award by the Ministry of Health Malaysia twice, both as a trainee and as a consultant.

He has published in multiple international peer-reviewed journals such as Fetal Diagnosis and Therapy, International Journal of Gynecology and Obstetrics, BMC Pregnancy and Childbirth, Journal of Obstetrics, Gynecology and Research, Journal of Obstetrics & Gynaecology and regularly involved in peer-review of manuscripts. Within the Ministry of Health, Dr Voon has co-authored numerous clinical practice guidelines/handbooks/protocols on labour and delivery, COVID-19, progesterone in pregnancy and maternal immunization. Having spent a significant proportion of his career in underserved, geographically-removed populations has helped him grow both as a clinician and as an individual. He finds maximizing outcomes with limited resources both challenging and fulfilling. He sees himself as a public health obstetrician and has particular interest in the use of ultrasound, prenatal screening, diagnosis and fetal therapy.



**Wong Peng Shyan**

Dato' Dr Wong Peng Shyan is currently the Head of Infectious Diseases Unit in Hospital Pulau Pinang, Malaysia. She graduated from the University of Malaya, Kuala Lumpur and obtained her MRCP (UK) in 2002. She did her Infectious Diseases training in Hospital Kuala Lumpur, Hospital Sungai Buloh, Royal Melbourne Hospital and Peter MacCallum Hospital, Australia. Her current interest is management of dengue and urological infections

**Yap Yok Chin**

Head of unit
Paediatric Nephrologist at Hospital Tunku Azizah Kuala Lumpur, Hospital Kuala Lumpur
Head of service Paediatric Nephrology Ministry of health

Paediatric Nephrology training 2003-2005

Hospital Sultanah Aminah, Johor Bahru
Hospital Kuala Lumpur
The Hospital for Sick Children, Toronto, Canada

Renal Transplant Service in Hospital Kuala Lumpur Since 2006

National renal registry, Malaysian Kidney Allocation system (MyKas) committee
Mentor for Paediatric Nephrology Fellowship Program



LIBEREZTADALAFIL **5MG 20MG****DUAL-ACTION
EFFICACY BEYOND
THE ORDINARY**SCAN QR
Abbreviated
Prescribing
Information
(API)**LIBEREZ****5mg****20mg**


References:

1. Coward RM, Carson CC. Tadalafil in the treatment of erectile dysfunction. Ther Clin Risk Manag. 2008 Dec;4(6):1315-30. doi: 10.2147/tcrm.s3336. PMID: 19337438; PMCID: PMC2643112. 2. Product Insert for Liberez 5mg & 20mg. 3. Giovanni Vanni Frajese, Flavio Pozzi & Gaetano Frajese (2006) Tadalafil in the treatment of erectile dysfunction; an overview of the clinical evidence, Clinical Interventions in Aging, 1:4, 439-449, DOI: 10.2147/cia.2006.1.4.439

Further information is available upon request.

PHARMANIAGA MARKETING SDN BHD (198401005734)

No. 7 Lorong Keluli 1B, Kawasan Perindustrian Bukit Raja Selatan, Seksyen 7, 40000 Shah Alam, Selangor Darul Ehsan, Malaysia.
Tel: 603-3342 9999 Fax: 603-3344 2222 Customer Care Line: 1-800-888-313 Email: customercare@pharmaniaga.com
Website: www.pharmaniaga.com

WELL-TOLERATED OVER
LONG-TERM TREATMENT ¹UP TO 36 HOURS
OF EFFICACY ³ENHANCED ERECTIONS WITH
ENDURING THERAPY ¹**D'Care PHARMACY**
德康药剂行

☎ : 010-9828260

✉ : dcare.pharmacy@gmail.com**Our Services:**

- * Customized Compounded Medications
- * JPA Medication Funding Support
- * Chronic Disease Medication Supply
- * Medication Counseling & Monitoring
- * Nationwide Delivery (Malaysia)
- * Pharmaceutical Supply to Clinics, Corporates & Institutions





AUSTRALIA



Lewis Chan

Head of Urology, Concord Repatriation General Hospital
Conjoint Professor Surgery, University of Sydney

Lewis Chan is Head of Urology at Concord Repatriation General Hospital and Conjoint Professor of Surgery at University of Sydney. His subspecialty interests are bladder dysfunction, geriatric urology and urological imaging. He has formal ultrasound training and has conducted courses in pelvic floor imaging in Australia, Asia, United Kingdom and United States. He is the co-Chair of the Concord Institute of Academic Surgery and coordinates an active basic sciences and clinical research program in functional urology with projects ranging from investigating bladder dysfunction with ageing to mesh complications and post prostatectomy incontinence. Dr Chan is the functional urology lead for the ROSE and RoboSling studies of the Sydney Local Health District Robotic Surgery Program evaluating functional outcomes of men undergoing radical prostatectomy. He is the editor of the textbooks 'Multidisciplinary Care of Urinary Incontinence' and 'Pelvic floor ultrasound- principles, applications and case studies'.



Marinelle DOCTOR

Urology Clinical Nurse Consultant, Nepean Hospital
Chair, NSW-ACT Section Australia and New Zealand Urological Nurses Society (ANZUNS)
Immediate Past Chair, Asian Urological Nursing Association (AUNA)

OBJECTIVE

Compassionate and dedicated Urology Nurse with 25 years of experience in providing high-quality patient-centered care in urological settings. Seeking to leverage expertise in catheter management, patient education, and interdisciplinary collaboration to enhance the quality of care and improve outcomes for patients in New South Wales. Committed to promoting best practices, supporting patients throughout their treatment journey, and contributing to a collaborative healthcare environment.

EXPERIENCE

- 2016-Current : Urology Clinical Nurse Consultant, Nepean Hospital
- 2014-2016 : Continence Clinical Nurse Consultant, Southwestern Sydney Local Health District
- 2006-2014 : Clinical Nurse Educator, Nepean Hospital
- 2008-2014 : Casual Clinical Facilitator, University of Western Sydney
- 2008-2014 : Casual Clinical Facilitator, College of Nursing
- 1995-2004 : Registered Nurse, Nepean Hospital
- 1993-1995 : Registered Nurse, De Vere Nursing Home
- 1992-1993 : Assistant in Nursing, Cardinal Freeman Nursing Home

EDUCATION

- Ongoing studies: Master of Nursing (Nurse Practitioner) University of Sydney
- 2015 : Master of Nursing, Charles Sturt University
 - 2008 : Certificate IV in Training and Assessment TAA 4014, Benchmark College
 - 2006 : Certificate IV in Training and Assessment BSZ98, Benchmark College
 - 2003 : Graduate Certificate in Acute Care Nursing, College of Nursing
 - 1993 : Bachelor of Nursing, University of Sydney

AWARDS AND ACKNOWLEDGEMENTS

- 2023 : Nursing and Midwifery Office Scholarship, \$ 10000
- 2022 : Emerald Award Australia and New Zealand Urological Nurses Society (ANZUNS), \$3500
- 2018 : Best New Presenter, ANZUNS Annual Scientific Meeting, \$1500
- 2016 : Australian College of Nursing and Allied Health Scholarship and Support Scheme, \$1500
- 2016 : Ferring Pharmaceuticals, \$750
- 2015 : Agency for Clinical Innovation, \$3000
- 2014 : Australian College of Nursing and Allied Health Scholarship \$7500
- 2014 : Nurse Reserve and Strategy Funding, Nursing and Midwifery Office, \$14000
- 2013 : Neurosurgical Nursing Professional Development Scholarship Committee, \$2000
- 2012 : Neurosurgical Nursing Professional Development Scholarship Committee. \$800

PROFESSIONAL MEMBERSHIPS

- Member, International Continence Society
- Member, European Association of Urology Nurses (EAUN)
- Member, Asian Urology Nurses Association (AUNA)





Marlon Perera

Consultant Urologic Surgeon
Robotic Uro-oncologic Surgeon
Peter MacCallum Cancer Center
Austin Health
Epworth Healthcare
Chair of Prostate Cancer Outcome Registry (Victoria)

Associate Professor Marlon Perera is an Australian-trained, award-winning urology surgeon who specialises in robotic surgery and uro-oncology. Dr. Perera has worldwide experience, having completed a PhD (Urology) and a prized-accredited 'Society of Urologic Oncology' (SUO) following at one of the world's best and most prestigious cancer centres – Memorial Sloan Kettering Cancer Center in New York City. He is the chair of the Prostate Cancer Outcomes Registry Victoria and also an editor of The British Journal of Urology, a one of the world's leading urology journals.

He is committed to providing the best evidence-based treatment and achieving the best possible outcomes for all his patients.



Weranga Ranasinghe

Associate Professor Weranja Ranasinghe is a consultant urologist and the Clinical Lead of Urologic Oncology Surgery at Monash Health. He is the binational lead for Urological Society of Australia and New Zealand Genito-Urinary Oncology Special Advisory Group.

A/Prof Ranasinghe graduated from the University of Bristol (UK) and completed his PhD at the University of Melbourne. He undertook specialist urology training in Australia (FRACS Urology) followed by the prestigious Society of Urologic Oncology fellowship at the MD Anderson Cancer Center in the USA. A/Prof. Ranasinghe is also an US DOD Early Career Research fellow at the University of Monash.

A/Professor Ranasinghe is an oncology editor for BJUI Compass and has authored over 100 peer-reviewed publications. His research in prostate cancer has been recognised through numerous national and international awards and competitive grant funding exceeding AUD 6.5 million.



Yap Hin Wai

Dr Hin Wai Yap is a highly accomplished and experienced urologist based in Toowoomba. With extensive qualifications and expertise in the field, Dr Yap is committed to providing the highest standard of care to his patients. Having obtained his medical degree from Kebangsaan University of Malaysia in 1985, Dr Yap went on to further his education with a Fellowship from the Royal Australasian College of Surgeons. He also holds a MFPHM from the UK. With a special interest in urology, Dr Yap has developed a deep understanding and expertise in the treatment of conditions related to overactive bladder (OAB). He is known for his commitment to staying up-to-date with the latest advancements in urological treatments and techniques, ensuring his patients receive the best possible care. Dr Yap is fluent in several languages, including Cantonese, Mandarin, and Malay. This enables him to effectively communicate with patients from diverse backgrounds and ensures that they fully comprehend their medical conditions and treatment options. With a patient-centered approach, Dr Yap takes the time to listen and understand his patients' concerns, providing them with personalized treatment plans that suit their individual needs. His compassionate and empathetic demeanor helps to put his patients at ease, building trust and fostering a positive doctor-patient relationship. Dr Yap's dedication to his field is evident in his involvement in ongoing research and professional development. He actively participates in conferences, workshops, and training programs to enhance his knowledge and skills, ensuring that he remains at the forefront of urological advancements. In his spare time, Dr Yap enjoys staying active and spending time with his family. He also enjoys giving back to the community and regularly participates in medical outreach programs to provide healthcare services to underserved populations. With his wealth of experience, commitment to excellence, and patient-focused approach, Dr Hin Wai Yap is a trusted and respected urologist who is dedicated to improving the lives of his patients.

**CHINA****Kai Zhang**

- Consultant, Department of Urology, Beijing United Family Hospital
- PhD, Erasmus University Rotterdam, Netherlands
- Committee Member and Secretary-General, Genitourinary Cancer Holistic Rehabilitation (CACA-GUHR), China Anti-Cancer Association
- Committee Member, Engineering Group, Chinese Urological Association (CUA)
- Committee Member, Genital Oncology, China Anti-Cancer Association (CACA-GO)
- Member, Asian Urological Surgical Training and Education Group (AUSTEG)
- Published over 40 papers in SCI and core journals, with a highest impact factor of 18.6 (JAMA Surgery, 2023, First Author)

**Wang He**

M.D. and Ph.D. Professor & Chief Physician of Urology Vice-director of Dept. of Urology
Sun Yat-sen Memorial Hospital, Sun Yat-sen University

- Outstanding youth of medicine in Guangdong Province
- Minimally invasive surgery committee member of CUA
- Minimally invasive and robotic surgery committee member of CUDA
- Secretary and committee member of GDUA

**FRANCE****Thomas Blanc**

Thomas Blanc (MD-PhD) is full Professor (academic position) in the Academic Pediatric Surgery Department of Necker-Enfants malades Hospital (AP-HP) in Paris (France) at the Faculté de Médecine, University Paris Cité.

He was trained as a medical student at Medical School – University of Paris Descartes Necker. He started his carrier at Necker in 2010 as a fellow in pediatric surgery and was then appointed as consultant pediatric surgeon and associate professor of pediatric surgery.

In his daily practice, he is particularly involved in pediatric urology (kidney surgery, hypospadias, exstrophy-epispadias, renal transplantation) and pediatric oncology (Wilms' tumor, neuroblastic tumors and rhabdomyosarcoma) and practices mini-invasive surgery and robot-assisted laparoscopic procedures.

He is Fellow of the European Academy of Paediatric Urology (FEAPU), member of the ESPU and the SIOP. He is course director of the Masterclass in Pediatric Urology. Professor Blanc is director of the multidisciplinary pediatric robotic program in Necker- Enfants malades Hospital. He is course director of the advanced course of Pediatric Robotic Surgery at the IRCAD.

Professor Blanc is also a committed researcher and writer with over 90 publications in international, peer-reviewed journals. In addition, Blanc is the co-author of several books dedicated to education in the field of pediatric surgery. Professor Blanc is the principal investigator of 2 studies : PECRoP (To Evaluate the Performance and Efficiency of Robotic Surgery in Children and Adults) NCT03274050 and EFUJA (Feasibility of Magnetic-end Double-J Ureteral Stent Use in Children) NCT04384939. Besides, he has a PhD in Cell Biology (Ph.D.) at University of Paris Descartes "Chronic kidney disease : from the genetic background to nephron 3D alterations" (Terzi Lab).





GREECE

**Athanasios Papatsoris**

Professor Athanasios Papatsoris graduated from Patras School of Medicine (honorary scholarship) from which he obtained also a MSc. Another MSc was obtained from Hellenic Open University in Health Management. His PhD was obtained at University of Athens. He was trained in London (UK GMC active member since 1997) and Athens. In London, he completed a 2-year Endourology fellowship (recognized by Endourological Society). Also, he completed a clinical fellowship in Laparoscopy in Le Mans, France, supported by EUSP. For 1 year he was honorary Consultant at Royal London Hospital. He holds honorary contract at Addenbrooke's Hospital, Cambridge and Imperial College and is Faculty member of Cambridge Medical Academy and member of Cyprus Medical Council with GHS license to practice.. He obtained a FEBU degree in 2007 (thereafter examiner/v. Chairman of the EBU Examination Committee). Dr Papatsoris is Full Professor of Urology at 2nd Department of Urology, School of Medicine, Sismanoglio Hospital, Athens Greece. Also, he is Visiting Full Professor of Urology Lebanese University, Adjunct Professor Guangzhou Medical University of China, Adjunct Professor of Urology, Icahn School of Medicine, Mount Sinai, NY USA, Visiting Professor of Carol Davila University Bucharest, University of Basrah Medical College, Astana Medical University Kazakhstan. and of Rwanda University, Invited Professor University of Medicine Tirana, Scientific Collaborator European University of Cyprus, honorable fellow of the PUA. Also, he is Assoc. Board member of ESOU (PCa Committee), EULIS, ESUT, ESAU, GAF, SEGUR and U-Merge. He is an uCARE SIU Board member, SIU Academy Endourology and IUA Board member. Also, for 4 years he was Secretary (General & Associate) of the Hellenic Urological Association (HUA), as well as Vice Chairman and Chairman of Section of Endourology-Laparoscopy, Chairman of Section of Oncological Urology and Board Member of HUA. He is Board member of the IMBE, European Medical Association Scientific Committee, Supreme Health Council member, Secretary General of Hellenic Genito-Urinary Cancer Group and Secretary of U-Merge. Full Professor Papatsoris h-Index is 47 (>250 publications in PubMed, >6300 citations). He is member of the Editorial Board in many medical journals, invited faculty in international congresses, workshops, intensive courses and live Endourology surgeries, advisor in Companies (eg Dyania Health, Phosprint) He has won the Endourological Society "Arthur Smith" award, the IAU outstanding contribution award and he is the Chairman of the ESD annual Congress.



INDIA

**Tarun Jindal**

Dr. Tarun Jindal is a leading Uro-Oncologist and robotic surgeon at Apollo Multispecialty Hospitals, Kolkata, India, with a distinguished profile in academic research and surgical innovation. He has authored more than 100 national and international publications, delivered numerous scientific presentations, and is recognized for pioneering minimally invasive approaches in urological cancers, especially in the field of minimally invasive groin surgery in penile cancer. His clinical practice is backed by a strong foundation in evidence-based medicine, and he remains actively involved in translational research, technological integration in surgery, and the mentorship of upcoming urologists.



INDONESIA

**Moh. Ayodhia Soebadi**

Head of the Urology Department at Universitas Airlangga, Indonesia

Dr. Yodi Soebadi is a urologist with particular interest in urogenital reconstruction, uroandiology, and endourology. He serves as Assistant Professor and recently appointed Head of the Urology Department at Universitas Airlangga, Indonesia, after coordinating the specialty training program since 2020.

He completed his medical degree (2005) and urology specialist training (2012), followed by a Ph.D. in Biomedical Sciences from KU Leuven, Belgium (2020). Dr. Soebadi is actively involved in Indonesian urological education and professional organizations, particularly in genitourinary reconstruction and andrology. He has contributed to national guidelines, international textbook chapters, and peer-reviewed publications.



**JAPAN****Takafumi Yanagisawa**

Dr. Takafumi Yanagisawa is a Lecturer in the Department of Urology at Jikei University School of Medicine, Tokyo, Japan. His clinical and research expertise lies in urologic oncology, particularly in systemic therapy for urological cancers, robotic surgery, and kidney transplantation. Dr. Yanagisawa has been instrumental in advancing evidence on en bloc transurethral resection for bladder tumors, as well as systemic treatments for advanced prostate, urothelial, and renal cell carcinomas. He has led numerous high-impact meta-analyses and real-world data studies, with recent work focusing on PSMA theranostics and immunotherapy for muscle-invasive and metastatic disease. He has published more than 200 peer-reviewed articles, including 45 as the first author, in leading international journals. He has been recognized internationally with awards such as the Best Researcher Award from the Medical University of Vienna and is frequently invited to speak at global congresses. Dr. Yanagisawa also contributes to academic training initiatives across Asia and Europe.

**Shuji Isotani**

Division of Urology, Juntendo University, Tokyo, Japan

Shuji Isotani, MD, PhD, is an Associate Professor in the Department of Urology at Juntendo University Graduate School of Medicine in Tokyo, Japan. He received his MD from Toyama Medical and Pharmaceutical University in 1996 and his PhD from Kobe University in 2000, followed by a research fellowship at Emory University in the United States. His clinical and research interests focus on minimally invasive urologic surgery, including RAPN, PCNL, and ECIRS, as well as endourology, 3D renal modeling, and surgical simulation and training. He has been contributing 3D imaging analysis of renal surgery and supported training methods by develop training model, and is actively involved in urological surgical education across Asia through AUSTEG. Dr. Isotani has authored numerous peer-reviewed papers and serves on several Japanese urological society councils.

**Takaaki Inoue**

Dr. Takaaki Inoue, M.D., Ph.D., a Japanese urologist born in 1977, is President of the Department of Urology at Hara Genitourinary Hospital and Visiting Professor at Kobe University, specializing in endourology, retrograde intrarenal surgery (RIRS), mini-ECIRS, ureteroscopy, and stone disease. Since earning his medical degree from Kansai Medical University in 2003, he has held multiple academic and clinical leadership roles, including Vice President of Hara Genitourinary Hospital and Head of its Stone Center. He holds numerous professional certifications in urology, oncology, laparoscopic surgery, and robotic assistance, and is an active committee member or director in several major Japanese and international endourology societies. Dr. Inoue has received many prestigious awards—including repeated “Best Doctors Japan” recognitions—and has published extensively with over a hundred peer-reviewed articles, reviews, and case reports centered on urinary stone management, surgical techniques, ergonomics, and innovative endoscopic technologies. An influential educator and global lecturer, he has served as faculty at major international meetings, hands-on surgical training programs, and collaborative research groups across Asia, Europe, and North America.

**KOREA****John Jang-Hwa Kim**

John Jang-Hwan Kim, MD is currently professor and chairman at the Department of Urology, Yonsei University College of Medicine in Seoul, Korea. He finished his residency at Yonsei University Severance Hospital and Neurourology and Female Urology Research Fellowship at the University of Pittsburgh, USA. He is the immediate past president of the Korean Continence Society and is actively serving as the President of the Korean Society for Urological Ultrasonography. Prof Kim conducts multiple research projects on functional urology including overactive and neurogenic bladders, benign prostatic hyperplasia, female urology and urological prosthetic surgery.





NEPAL



Suman Chapagain

Dr Suman Chapagain is a consultant Urologist with keen interest in minimally invasive Urological Surgeries (Laparoscopic and Robotic).

He is current Secretary General of Nepal Association of Urological Surgeons(NAUS).

He is Assistant Professor in Depart of Urology and Kidney Transplant Surgery, Maharajgunj Medical Campus, TU Teaching Hospital, Tribhuvan University, Kathmandu, Nepal. He also serves as Chief of Urological Services in Hospital for advanced medicine and Surgery (HAMS) Kathmandu, Nepal.

He is well known for his contributions as faculty at national and international conferences, conducting workshops and delivering lectures. He also has more than forty publications in peer- reviewed journals.



PHILIPPINES



Arturo P. Castro, Jr

Dr. Art Castro Jr. is a board certified Urologist with post graduate training in Minimally Invasive Surgery. He is a Diplomate of the Philippine Board of Advanced Minimally Invasive Surgery. He is a Fellow of the Philippine Urological Association, the Philippine College of Surgeons, and the Philippine Association of Laparoscopic and Endoscopic Surgeons. He is an International member of the American Urological Association. He is a member of the Philippine Endourological and Robotics Society and Philippine Society of Urologic Oncologists. He is skilled and competent in both open and minimally invasive surgery both for benign and malignant diseases of the genito-urinary tract. He has published and presented papers internationally on Robotic, laparoscopic and needle ablative treatments.

AFFILIATIONS

Fellow, Philippine Urological Association
Fellow, Philippine College of Surgeons
Fellow, Philippine Association of Laparoscopic and Endoscopic Surgeons
International Member American Urological Association
Member Philippine Endourological and Robotics Society
Member Philippine Society of Urologic Oncologists
Member Asia-Oceania Research Organization for Genital Infections and Neoplasia



SINGAPORE



Benjamin Goh

Senior consultant Urologist and Kidney Transplant Surgeon
National University Hospital, Singapore
Associate Professor of Surgery
National University of Singapore.

Benjamin Goh is a Senior consultant Urologist and Kidney Transplant Surgeon at the National University Hospital, Singapore and an Associate Professor of Surgery in National University of Singapore.

Benjamin's area of interest includes Robotic kidney oncologic surgery, reconstruction and kidney transplantation. He completed a 1 year double fellowship programme at the Royal Free Hospital in London UK in 2018-2019 in Robotic Kidney Surgery and Kidney Transplantation.

Benjamin is a passionate medical educator who was the previous Undergraduate Surgical director for Yong Loo Lin School of Medicine NUS and recently stepped down as Assistant Dean of Students.

His other interests include executive coaching, team coaching and organization development for different sectors around the world.



Henry HO

Chairman for Division of Surgery and Surgical Oncology,
Singapore General Hospital and National Cancer Centre Singapore

Henry HO is the Chairman for Division of Surgery and Surgical Oncology, Singapore General Hospital and National Cancer Centre Singapore; Academic Chair for Surgery Academic Clinical Program, SingHealth. Currently A/Prof Henry is also holding the appointment as Director for SingHealth Duke-NUS Innovation Centre.

A/Prof Henry is a urological surgeon that specializes in robotic surgery for urological cancers such as prostate & kidney. He received his MBBS and Master of Medicine (Surgery) from the National University of Singapore. After his accreditation as a Urologist, he further specializes with fellowships in robotic surgery in University of Innsbruck, Austria and Stone surgery in Hamburg, Germany.

A/Prof Henry is an advocate for innovation in his clinical career. He is an early adopter of new technology with robust scientific methodology. Amongst his many publications, the randomized control trial on bipolar technology for prostate enlargement changes the practice of urologist internationally.

He went on to be an innovator with the invention of Mona LisaTM transperineal prostate biopsy device (Biobot Surgicals Pte Ltd). He brought this project from a research project to commercial company. The device provide safe and accurate diagnosis of prostate cancer in men. It is used in many Singapore hospitals, Germany, Australia and China.

A/Prof Henry also contributes to the Singapore innovation ecosystem. He was the first doctor in SGH/SingHealth to be awarded the Singapore-Stanford Biodesign Fellowship Award by A*STAR in 2011. He started the Medical technology Office (MTO) in Singhealth to help more clinicians onto this innovation journey. Its goal is to nurture doctors, nurses and allied health with grants and technology matching to become clinician-innovators. His NMRC is Co-chair of the Clinician-innovator taskforce and Chair for clinician-innovator development grant.

A/Prof Henry leads the clinical test-bedding and adoption in Singhealth-DUKE NUS Academic Medicine Innovation Institute which aims to facilitate implementation of technologies with external partners into the healthcare system. to imbue such vibrant exchange and collaboration (Digital, technology and process), there will be a healthcare Innovation and transformation center.



Jia-Lun Kwok

Consultant and Endourology Service Lead
Department of Urology
Tan Tock Seng Hospital, Singapore

Dr Jia-Lun Kwok is a Consultant and Endourology Service Lead with the Department of Urology at Tan Tock Seng Hospital, Singapore. Dr Kwok completed advanced training with a one-year Endourology Fellowship at University Hospital Zurich, Switzerland. His areas of interest are endourology (PCNL, ECIRS, URS, FANS), stone disease and benign prostate conditions. Dr Kwok is the Program Director of the National Healthcare Group (NHG) Urology Residency Program. He holds teaching appointments with National University of Singapore (NUS) and Nanyang Technological University (NTU). Dr Kwok is a keen researcher in the field of Endourology, with international collaborations. He is a member of the Progressive Endourological Association for Research and Leading Solutions (PEARLS), Paris, France. He is also an associate member of the Section of EAU Endourology, and the Asian Urological Society of Endoluminal Surgery & Technology (AUSSET).



Tiong Ho Yee

Senior Consultant, Department of Urology,
National University Hospital, Singapore

A/Prof Tiong Ho Yee graduated with Honours from the University of Nottingham, UK in 1997. He received his membership of the Royal College of Surgeons of England in 2001 after completing a General Surgical residency at the University of Leicester Hospital Systems, UK. During his subsequent Urology residency at National University Hospital (NUH), completed in 2006, A/Prof Tiong was awarded the Singapore Urological Association-European Board of Urology Book Prize in 2005 and 2007. He has been a Fellow of the Academy of Medicine, Singapore since 2007. As a recipient of the Ministry of Health Human Manpower Development Plan (HMMDP) scholarship, A/Prof Tiong also completed a two-year clinical fellowship training in Kidney and Pancreas Transplantation at the Cleveland Clinic, Ohio, USA. He worked under the mentorship of the Glickman Urological and Kidney Institute faculty, ranked No.1 in the United States, to gain expertise in his current areas of interest – Kidney Surgery and Transplantation.

In 2009, he was certified and became a full member of the American Society of Transplant Surgeons. He is a certified transplant surgeon by the Ministry of Health, Singapore, serves on its advisory committee for transplantation, and is appointed as the Director of the National Pancreas Transplant Programme. At NUH, he is the Director for Kidney Surgery and Transplantation (Department of Urology), the Surgical Director for the Adult Kidney Transplantation Programme and Programme Director for Adult Pancreas Transplantation (National University Centre for Organ Transplantation), as well as the Programme Director of Urology Residency (National University Health System).

A/Prof Tiong aims to consistently lead in the field of kidney cancer surgery by performing minimally invasive kidney sparing surgery for localized cancers, as well as major open curative operations for advanced kidney cancers and transplantations. At NUH, he started the Da Vinci Robotic Kidney Surgery program with published outcomes for our kidney cancer patients using this surgical technique. With research and dedication, A/Prof Tiong believes in delivering patient-centric care and holistic management of his cancer and transplant patients.



TAIWAN



Jacob See-Tong Pang

Professor Jacob See-Tong Pang graduated from Chung-Shan Medical University, Taichung, Taiwan. Upon completion of his medical and surgical residency training and driven by his strong interest in medical research, he pursued his advanced study at the Karolinska Institute, Sweden and obtained his PhD degree in 2003. He was the chief of Department of Uro-Oncology at Chang Gung Memorial Hospital from 2007 to 2014, and vice-superintendent of the Chang Gung Memorial Hospital (CGMH), LinKou from July 2017 till June 2023. He completed the first robotic surgery at Chang Gung Memorial Hospital in October, 2006, since then he has completed nearly 1500 robotic surgeries including prostatectomy, partial nephrectomy, cystectomy, nephroureterectomy and etc. Prof. Pang actively involves in both clinical and translation research. His research effort focuses on understanding and improving clinical outcomes of patients with urological cancer. Of note, he co-led the research team to elucidate the mutational signature of aristolochic acid-associated upper urinary tract urothelial cell carcinoma (UTUC) and published the results in Science Translational Medicine. Thus far, he has published more than 160 peer-reviewed articles in many renowned medical journals. He is also the immediate past president of Taiwan Urological Association (TUA), and currently the president-elect of Urological Association of Asia (UAA).



THAILAND



Passakorn Amnatrakul

Consultant in Urology, Division of Urology, Lerdsin General Hospital,
Department of Medical Service, Ministry of Health.

- Member of Thai Urological Association (TUA) and Thai Uro-Onco Society (Thuos)

Education:

- Doctor of Medicine (M.D.), 1999-2005, from Chulalongkorn University.
- Earned a Diplomate, Thai Board of Urology (2008-2012) from Chulalongkorn university.
- Completed a Clinical observership in robotic surgery (2016-2017) at Guy's hospital, London, UK.

Experience:

- Served as Urology consultant at Maharaj hospital (2012-2014), and as Urology consultant at Lerdsin General Hospital (2014-Now).

Fields of interest:

- Uro-oncology, Minimally invasive surgery and Endourology.



Tanet Thaidumrong

Assistant Professor of Surgery
College of Medicine, Rangsit University, Thailand

Asst. Prof. Tanet Thaidumrong is an Assistant Professor of Surgery at the College of Medicine, Rangsit University, and serves as Secretary General of the Thai Urological Association (2023–2025). He is a urologist at Rajavithi Hospital in Bangkok, specializing in minimally invasive and robotic urological surgery, and holds leadership roles as Director of MIS Urology at Rajavithi and as former Director of the 11th Public Health Region of Thailand. Dr. Tanet completed advanced fellowships in laparoscopic and robotic urology in France and has authored pioneering publications on laparoscopic and robotic prostatectomy, nephrectomy, and cystectomy in Thailand. He has earned recognition for both technical innovation and academic leadership in Thai urology, contributing extensively to clinical research and urology training.



UNITED ARAB EMIRATES



Mohamad Fakhri

- Holder of a Master's of Science in Nursing and health care leadership with 20 years of healthcare experience spread across different countries in the Mena Region (UAE, Saudi Arabia, Egypt, and Lebanon) with focus on health care leadership, health care startups, quality, and patient safety. Restructuring, team building, staff empowerment, and healthcare entrepreneurship. Highly skilled in staff, and patient engagement and an expert in launching and commissioning hospitals, where he participated in commissioning and starting up and management 9 different hospitals in United Arab Emirates, KSA, Egypt, and Lebanon.
- Currently affiliated with Fakeeh University Hospital as Chief Nursing Officer, and a Medical Director for Fakeeh Home Health care. A consultant for the Australian Council for Healthcare Standards (ACHS) on nursing excellence, evidence-based practice in nursing, staff engagement initiatives, shared governance models implementations, quality, patient safety, and risk management.
- Served as a Chief Nursing officer for highly reputed, large-scale hospitals in UAE and the region, and participated in implementing quality, patient safety, and patient engagement standards through preparing nursing departments to major accreditations and certifications like JCIA, ACHS, Planetree, and Magnet designations.



UNITED KINGDOM

**Asif Muneer**

Professor Asif Muneer completed his surgical training in Manchester, Oxford and London. He has also received funding to undertake fellowships to the University of Paris, University of Bern and MD Anderson, Texas as well as the NKI in Amsterdam. He has held a number of national roles including Chair BAUS Section of Andrology and Genitourinary Surgery, President British Society for Sexual Medicine and is past Honorary Secretary British Association of Urological Surgeons. He is an Executive Committee member for the European Society for Sexual Medicine.

He has received a number of awards including the Keith Yeates Gold Medal for the FRCS(Urol) which is awarded by the intercollegiate board and the Harold Hopkins Golden Telescope Award presented by the British Association of Urological Surgeons to consultants for their contribution to urology within the first 10 years of a consultant appointment. Currently he is the only person to have received both accolades as a trainee and a consultant.

**Christopher Eden**

Christopher Eden attended Guy's Hospital and King's College Hospital Medical Schools, London, achieving an MBBS in 1985 from the University of London after winning Surgery and Paediatric Prizes. He became a Fellow of the Royal College of Surgeons in 1995 and was awarded a Master of Surgery degree from the University of London in 1997.

As a surgical trainee he became a pioneer of minimal access urological surgery, having performed the UK's first laparoscopic pyeloplasty in 1994, first laparoscopic radical prostatectomy in 2000, first laparoscopic radical cystectomy in 2001, first robotic and laparoscopic Retzius-sparing RARP in 2016, first Single Port robotic Retzius-sparing radical prostatectomy in Europe and first Single Port robotic radical prostatectomy in the UK in April 2024 and the first Single Port robotic transvesical radical prostatectomy in Europe in June 2024. He has one of the world's largest personal series of major minimal access urological procedures at over 5,000 cases and has published more than 50 peer-reviewed papers on laparoscopic and robotic urology, 9 book chapters and a book.

**Grenville Oades**

Consultant Urologist
Queen Elizabeth University Hospital, Glasgow

Currently based at Queen Elizabeth University Hospital, Glasgow, Gren brings a wealth of experience of NHS Scotland along with his knowledge of the Scottish kidney cancer landscape to our Board of Trustees.

Starting as an undergraduate in Edinburgh, Gren trained in general surgery in Newcastle-Upon-Tyne before completing an MD the University of London. He returned to Scotland in 2002 where he completed his urological training.

He has an interest in renal cancer and minimally invasive surgical treatments, is a member of the NCRI (National Cancer Research Institute) Renal Cancer Surgical subgroup and is involved with several national and international medical trials. Gren has previously chaired the West of Scotland Managed Clinical Network for Urological Cancers and, with three colleagues, provided tertiary referral services for the West of Scotland.



UNITED STATES OF AMERICA

**Leonard G Gomelia**

Dr. Leonard G. Gomella, MD, is a leading urologic oncologist specializing in **prostate cancer and urologic oncology**, serving as the **Bernard W. Godwin Professor of Prostate Cancer** and **Chairman of the Department of Urology** at Sidney Kimmel Medical College of Thomas Jefferson University, as well as **Senior Director of Clinical Affairs** at the Jefferson Kimmel Cancer Center. He earned his medical degree and completed his residency at the **University of Kentucky**, followed by a prestigious fellowship at the **National Cancer Institute's Surgery Branch**. Board-certified by the **American Board of Urology** and a **Fellow of the American College of Surgeons (FACS)**, Dr. Gomella is recognized for his significant clinical, academic, and leadership contributions to the field of urologic oncology.





A moderately complex Robotic Retzius Sparing Prostatectomy case, focusing on nerve-sparing, bladder neck preservation, apical dissection, and anastomotic techniques: How I do it?

Asst. Prof Tanet Thaidumrong, MD.

Division of Urology, Rajavithi Hospital, Bangkok, Thailand

Robotic Retzius-sparing radical prostatectomy (RS-RARP) is an advanced minimally invasive technique, optimizing both oncologic control and functional recovery in prostate cancer surgery. By approaching the prostate posteriorly, this method preserves anterior structures critical for urinary continence and sexual function. Key to success in RS-RARP is meticulous nerve-sparing: the neurovascular bundles are precisely identified and separated with robotic instruments, minimizing trauma and maximizing preservation for enhanced postoperative continence and potency. Bladder neck preservation, performed by sharp and blunt dissection, maintains sphincteric muscle fibers and supports early return of continence. Apical dissection, using techniques such as the “collar” approach, reduces apical positive surgical margins while preserving urethral sphincter length, balancing oncologic safety with functional outcomes. Finally, robust anastomotic techniques—employing barbed running sutures and posterior reconstruction—secure watertight reattachment of the bladder and urethra, supporting rapid recovery and reduced complications. RS-RARP thus highlights expert integration of surgical innovation and precision to deliver superior outcomes in complex prostate cancer cases.

Making ESWL Great Again

Git Kah Ann

Consultant Urologist, Pantai Hospital Penang, Malaysia.

Extra-corporeal Shock Wave Lithotripsy (ESWL) has been used to fragment urinary calculi for more than 4 decades since it was first used in 1980. It has come a long way since the first Dornier HM3 with a water bathtub in a large room to a small trolley mounted modular lithotripter. Lithotripter technology has also progressed in terms shock-wave generation and coupling. Stone localization has also improved with the advancement of high-definition imaging, ultrasound clarity and Doppler technology. Technical skill and structured guidance and training have continued to be more established.

Case scenarios will illustrate the importance of having ESWL in the armamentarium of an established Urologist treating urolithiasis. There are also occasions when ESWL plays a significant role in the management of urinary stones.

Ultrasound localization has made ESWL great again by improving accurate real-time localization, zero-radiation and early identification of complications. Results are much superior to conventional fluoroscopic localization and approaching results of modern endoscopic modalities minus requirement of general anaesthesia and ability for out-patient treatment.

Conclusion

ESWL will be great again with the advancement of lithotripter technology, clear, accurate and high-definition imaging, ultrasonic localization and urologists adopting superior technique.

Keywords

Extra-corporeal Shock Wave Lithotripsy, Technology Advancement, Ultrasonic localization, ESWL Technique

AI in Prostate Cancer Care – Hype or Real Progress

A/Prof Weranja Ranasinghe

MBChB, PhD, MRCSEd, FRACS (Urol), FUSANZ

Urologist | Uro-Oncologic Surgeon, Monash Health & Austin Health

Clinical Lead, Urologic Oncology Surgery, Monash Health

Lead, Urologic Society of Australia and New Zealand GU Oncology Special Advisory Group

Artificial intelligence (AI) is rapidly transforming prostate cancer care, from diagnosis through to long-term follow-up. This lecture will explore how AI has enhanced diagnostic accuracy through MRI interpretation and pathology grading, refined risk stratification and treatment selection, and supported decision-making in active surveillance, surgery and radiation therapy. It will also discuss emerging tools that personalise care, predict progression, and address patient anxiety through digital engagement. This session will critically examine whether AI in prostate cancer truly represents meaningful clinical progress or technological hype.





Robotics in Functional and Reconstructive Urological Surgery

Lo Hwa Loon

Hospital Kuala Lumpur

Robotic functional and reconstructive urology is among the most swiftly advancing fields in contemporary urologic surgery, merging the accuracy of robotic technology with the intricate requirements of reconstructive interventions. The advent of the robotic platform has revolutionised surgeries that previously necessitated wide open incisions—such as ureteral reimplantation, pyeloplasty, bladder neck reconstruction, urethral reconstruction, and urinary diversion—into minimally invasive techniques characterised by enhanced visualisation, dexterity, and precision.

Robotic assistance facilitates precise dissection, tension-free anastomosis, and improved suturing in restricted areas like the pelvis or retroperitoneum. This has resulted in less blood loss, shorter hospital stays, speedier recovery, and equivalent or enhanced functional results relative to open surgery. In reconstructive urology, it is mostly utilised for disorders like ureteral strictures, vesicovaginal and urethral fistulae, bladder augmentation, and urine diversion following cystectomy and anti-incontinence procedures such as artificial urinary sphincter insertion, pubovaginal sling and bladder neck reconstruction.

Recent advancements include the application of fluorescence imaging (e.g., indocyanine green) for evaluating tissue perfusion, three-dimensional preoperative planning, and the incorporation of artificial intelligence for intraoperative guidance. Notwithstanding increased expenses and the requirement for specialised training, robotic reconstruction is proliferating worldwide as expertise and data accumulate—providing patients with a minimally invasive option that boasts elevated functional success rates and reduced morbidity.

Antibiotic stewardship in Urology. Navigating Resistance in Era of Overuse

Wong Peng Shyan

Hospital Pulau Pinang

Antimicrobial resistance (AMR) is a major global threat driven by inappropriate use of antimicrobials and worsened by the lack of new treatments. Strategies to combat AMR include promoting antimicrobial stewardship (AMS), implementing robust surveillance systems, and improving laboratory diagnostic tools to enable targeted antimicrobial selection as well as strengthening infection control and prevention measures. A case study and approach to AMS in Urology will be discussed.

MRI-targeted vs Systematic Biopsies: Should we Eliminate Random Biopsies?

Tan Guan Hee

Sunway Medical Centre

The diagnostic pathway for prostate cancer is undergoing a significant transformation with the integration of multi-parametric MRI (mpMRI). While traditional systematic, or random, biopsy has been the historical standard, it is prone to undersampling clinically significant cancer (csPCa) and over-detecting indolent disease. The advent of MRI-targeted biopsy, which focuses on suspicious lesions identified pre-biopsy, offers a more precise approach.

This presentation will discuss evidence comparing MRI-targeted and systematic biopsy strategies. Data from pivotal trials demonstrates that targeted biopsies alone detect comparable amount of csPCa while significantly reducing the diagnosis of clinically insignificant cancer. However, the question of completely eliminating systematic biopsies remains contentious. A minority of csPCa can be invisible on mpMRI, and concerns persist about missing these cases with a targeted-only biopsies. We will discuss real-world experience and results to better understand how we can improve on this very crucial step in the management of prostate cancer.



FAUA-TUA LECTURE: The Role of Active Surveillance for Small Renal Cancers. Are we Overtreating?

Passakorn Amnattrakul

Lerdsin hospital
Department of Medical Service
Ministry of Health, Bangkok

The increasing incidental detection of small renal masses (SRMs, cT1a, size <4 cm) necessitates a critical assessment of intervention versus observation strategies, addressing the concern of overtreatment.

Historically, Radical Nephrectomy (RN) was often applied, resulting in its documented overutilization for localized disease and subsequent negative impact on renal function. Active Surveillance (AS), defined as initial monitoring by serial abdominal imaging with delayed intervention reserved for progression, capitalizes on the often indolent biology of small renal mass.

AS is a standard management strategy, particularly acceptable for solid masses < 2 cm, given their high rate of benign histology and low metastatic potential. For properly selected patients, retrospective and prospective data confirm a low risk of metastatic progression over the initial three years.

Patient counseling must involve shared decision-making that critically weighs the patient's age, comorbidities, and life expectancy against the risks of surgical morbidity and progressive Chronic Kidney Disease (CKD).

AS should be prioritized when intervention risk or competing risks of death outweigh potential oncologic benefits. Renal Mass Biopsy (RMB) is integral for oncologic risk stratification when the clinical risk/benefit profile is equivocal. Triggers for intervention typically include substantial growth, often defined by median rates exceeding 5 mm/year, suggesting oncologically active disease.

The modern management paradigm utilizes AS and risk stratification tools to minimize over treatment, confirming AS as a safe and effective approach that preserves nephrons without compromising short- to interoncologic outcomes in appropriate candidates.

Single Port Retzius Sparing and Intraoperative Assessment of Margins

Christopher Eden

Professor of Urology, University of Surrey,
Consultant Urological Surgeon at The Royal Surrey County Hospital, Guildford, UK and Co-Director of Santis.

Intuitive Surgical's Single port robot was granted FDA approval in 2016 but its launch outside the US was significantly delayed by the Covid pandemic. It allows surgeons to use novel points of access into the body, reduces post-operative opiate requirement, allows earlier discharge from hospital and reduces morbidity from surgery in previously-operated patients.

Intraoperative assessment of surgical margin status allows radical prostatectomists to maximise both cancer control and functional outcomes.

FAUA-SUA LECTURE: The Role of Minimally Invasive Surgery in Kidney Transplantation: A Game Changer or a Niche Technique?

Benjamin Goh

Senior consultant Urologist and Kidney Transplant Surgeon
National University Hospital, Singapore
Associate Professor of Surgery in National University of Singapore.

Minimally invasive surgery has reshaped kidney transplantation, especially in living donor nephrectomy, by reducing morbidity while maintaining excellent graft outcomes. This talk outlines the evolution from open donor nephrectomy—long the gold standard for safety—to laparoscopic approaches, which enhanced recovery, cosmesis, and donor acceptance.

It will also highlight the emerging role of robotic-assisted kidney transplantation, where technology extends minimally invasive principles to the recipient procedure. Together, these advances continue to refine surgical practice, expand donor pools, and improve outcomes in renal transplantation.

UAA Lecture: En-Bloc Resection of Bladder Tumor- What's New Beyond the Horizon?

Takafumi Yanagisawa

Department of Urology, The Jikei University School of Medicine

Conventional transurethral resection of bladder tumor (cTURBT) has been the standard technique for over nine decades but remains limited by tumor fragmentation, which compromises pathological assessment and potentially increases the risk of tumor cell seeding. En bloc resection of bladder tumors (ERBT), first described in Japan in 1980, preserves the architectural integrity of the specimen, enabling higher rates of detrusor muscle retrieval, reliable evaluation of resection margins, and improved pathological substaging—particularly for T1 disease. Recent randomized controlled trials (RCTs) and meta-analyses demonstrate that ERBT is associated with reduced rates of obturator nerve reflex and bladder perforation and allows shorter catheterization periods compared with cTURBT, although the operative time tends to be slightly longer. Notably, a recent multicenter phase 3 RCT reported a significant reduction in 1-year recurrence rates with ERBT in selected patients with non-muscle-invasive bladder cancer, highlighting the potential oncological benefit of high-quality resection. Key challenges for wider adoption include defining optimal patient selection criteria, standardizing surgical techniques, and enhancing training for young surgeons. Advances in device development, including transurethral robotic platforms, may further facilitate precise ERBT and broaden its applicability. Continued accumulation of high-quality evidence is essential to establish ERBT as a new standard of care in the management of bladder cancer.

Transitioning from Resident to Consultant

Consultant Urologist

St Andrews Toowomba Hospital
Australia

The 4-5 years of Urological Training aim to prepare one for independent practice on completion. The RACS encourages the Board of Urology to fulfill the 9 core competencies, and this is examined by the Court as well as reviewed in Audit.

Despite the attention to core detail, there is still that unfilled gap that is either not verbalised or appreciated. There is often an initial loss especially in the initial transition years.

After discussion with various people at different levels, I hope to provide an opinion as to where we can help and focus the transition to a smoother Consultant Practice.

Urological Training Opportunities in Australia (and New Zealand)

Consultant Urologist

St Andrews Toowomba Hospital
Australia

With changes by the Board of Urology to training over the past 8 – 10 years, there has been distinct changes to Fellowship opportunities for non-residents. There is also a tightening to IMG pathways.

After many conversations, I hope to provide a broad view of training/Fellowship opportunities in Australia (New Zealand). Hopefully this will provide for a better appreciation and more realistic approach to considering Australia as a place to further training and experience.



Pelvic floor ultrasound : Should it be a Routine Practice for Assessment of Female Urological Problems Nowadays?

Lewis Chan FRACS, DDU
Head of Urology
Concord Repatriation General Hospital
Conjoint Professor of Surgery at University of Sydney

There is increasing interest in using ultrasound for assessment of voiding dysfunction, pelvic organ prolapse and mesh complications. Ultrasound equipment is widely available and this modality allows dynamic imaging of the pelvic floor to assist the clinician in diagnosis and management. This lecture will cover the applications of ultrasound imaging in assessment of urinary incontinence, failed slings, pelvic organ prolapse and evaluation of mesh complications.

The Future of ED Treatment; Penile Prosthesis vs Regenerative Therapy

Asif Muneer
Consultant Urological Surgeon And Andrologist And Clinical Lead For Urology at UCLH.

Erectile dysfunction (ED) refractory to pharmacological therapy remains a challenge. Penile prosthesis implantation has long represented the definitive surgical solution, offering predictable, durable outcomes and high patient satisfaction and low complication rates. Advances in device design, antibiotic coated devices and minimally invasive techniques continue to refine penile prosthesis surgery. In parallel, regenerative therapies—such as stem cell therapy, platelet-rich plasma, gene therapy, and tissue engineering—aim to restore erectile function by reversing endothelial dysfunction, enhancing neurovascular repair, and regenerating smooth muscle architecture. Early-phase trials suggest potential benefits, but long-term efficacy, safety, and regulatory approval remain unproven. The future management of ED may evolve toward a hybrid model, with penile prosthesis surgery reserved for advanced structural disease and regenerative approaches offered earlier in the disease trajectory.

Varicocele Repair for Male Infertility – Necessary or Overused?

Asif Muneer
Consultant Urological Surgeon And Andrologist And Clinical Lead For Urology at UCLH.

The presence of a varicocele is often detected in men presenting with a history of infertility. The relationship with male factor infertility is multifactorial, involving testicular hyperthermia, oxidative stress, and impaired venous drainage, Leydig cell dysfunction - all of which adversely affect spermatogenesis. Varicocele repair has been shown to improve semen parameters, sperm DNA integrity, and, in selected patients, natural pregnancy rates. Microsurgical varicocelectomy, particularly via the subinguinal approach, is considered the gold standard owing to its high success rates and low risk of complications, including low rates of recurrence and hydrocele formation. While assisted reproductive technologies (ART) remain an alternative, varicocele repair offers a cost-effective and natural improvement in fertility potential. The lecture will provide an overview of current guidelines and evidence in relation to varicoceles and fertility outcomes.

Innovation in stone surgery – Are we at the peak or just getting started?

Takaaki Inoue MD, PhD
Urologist, Visiting Professor at Kobe University, and President of Hara Genitourinary Hospital in Japan.

Endourological development has dramatically risen in stone field for only a few years. These advancements have been changed our technical procedure and mind from fragmenting with basket removal to dusting with suction devices. Simultaneously, to seek more effective outcome and to make tiny dusts, laser technology has been advancing as well like TFL, Pulse modulation of Holmium YAG laser, and Thulium YAG laser. Now, there are some ex-vivo and clinical evidences which TFL seem to be superior to others. However, I am wondering if TFL is really superior laser in any situation/cases. On another hand, robotic assisted RIRS is one of topics in endourology for treatment of upper urinary tract diseases, which has some advantages such as better ergonomics, less radiation exposure, and standardization of FURS manipulation. However, what are advantage for patients which is biggest concerns now. Therefore, this is still under investigation. Further topic is saline irrigation. That is my main concern because endoluminal surgery needs to control running saline into limited collecting system. Irrigation would be key for our endoluminal surgery to keep safe and effective for patients. Today, I would like to focused on "irrigation".



Advances in the Surgical Management of BPH: Advent of Bipolar TURP and Utility of Holmium and Thulium Lasers

Arturo P. Castro Jr., MD, DPBU, DPBAMIS, FPUA, FPCS, FPALES

Background:

Benign prostatic hyperplasia (BPH) is the most common Urological disease in aging men. Transurethral resection of the prostate (TURP) using Monopolar technology is traditionally considered the gold standard, but limitations such as bleeding risk, fluid absorption, and size restrictions spurred the development of safer, more versatile surgical modalities.

Methods:

This talk reviews the evidence and practical considerations surrounding three contemporary techniques: Bipolar TURP, Holmium laser enucleation of the prostate (HoLEP), and Thulium laser procedures (ThuLEP, ThuVEP, ThuVAP). Clinical outcomes, advantages, limitations, and guideline recommendations are discussed.

Results:

Bipolar TURP uses saline irrigation, theoretically preventing TUR syndrome. It offers better hemostasis decreasing transfusion rates while maintaining comparable symptom and flow improvements to monopolar TURP. HoLEP boasts of complete anatomic enucleation, demonstrating size-independent efficacy, safety even in anticoagulated patients, and durable results exceeding 10 years, though with a steep learning curve. Thulium laser techniques provide continuous-wave energy with excellent hemostasis, versatile application (vaporization and enucleation), and clinical outcomes equivalent to HoLEP and TURP, though long-term comparative data remains limited. Guideline recommendations increasingly recognize HoLEP as a size-independent gold standard, while Bipolar TURP and Thulium approaches are valuable alternatives based on patient selection, institutional resources and surgeon training.

Conclusion:

Bipolar TURP is an effective, accessible option for medium-sized glands. Its technique is familiar to all Urologists. Laser enucleation with Holmium or Thulium is fast establishing itself as the most durable and size-independent surgical approach. The future of BPH surgery is focused on enucleation techniques, the universal adoption of these techniques is dependent on surgeon training, treatment cost, and availability of the required equipment.

Laser Performance: Concepts in the Era of Advanced Lasers, Suction and FANS

Jia-Lun Kwok

Consultant and Endourology Service Lead
Department of Urology
Tan Tock Seng Hospital, Singapore.

In the treatment of urolithiasis, there has been development of laser technology including pulse modulation and expansion into Ho:YAG, TFL and pulsed Tm:YAG platforms, with a need for standardization in reporting laser performance. The era of suction has established itself in flexible ureteroscopy, percutaneous nephrolithotomy and endoscopic combined intrarenal surgery. Understanding laser performance with these adjuncts become even more important.

USI LECTURE: Evolving Standards: Can Minimally Invasive Inguinal LND Replace Open?

Tarun Jindal

Uro-Oncologist and Robotic Surgeon
Apollo Multispecialty Hospitals, Kolkata, India,

Inguinal lymph node dissection is a morbid procedure. It is associated with an almost 30% risk of wound complications. Video endoscopic inguinal lymph node dissection (VEIL) is a minimally invasive technique that can decrease the morbidity of open groin dissection. The oncological outcomes of VEIL are similar to the open approach. The VEIL can be performed by both, laparoscopic and robotic approaches. The conventional technique of VEIL has certain technical issues like space constraints, external clashing of robotic arms, lack of space for the assistant, clashing of the arms with the knee, etc. We describe the technique of robotic VEIL especially by the lateral approach which can circumvent all the major issues of conventional open surgery.



Elevating Nursing Practice in Robotic Surgery – Robotic Nursing Aspect

Robotic surgery represents a major advancement in surgical technology, requiring nurses to expand their knowledge, technical skills, and critical thinking. In the robotic nursing aspect, elevating practice involves enhancing competency in robot setup, system troubleshooting, patient safety, and multidisciplinary teamwork. Robotic nurses play a vital role in ensuring smooth workflow before, during, and after surgery. They must be proficient in instrument docking, equipment calibration, and sterile handling of robotic arms and instruments. Continuous education, simulation training, and evidence-based practice are essential to maintain competency and confidence in managing complex robotic procedures. By adapting to technological advancements, robotic nurses elevate the quality of perioperative care, improve surgical outcomes, and contribute to the overall safety and efficiency of robotic-assisted surgery.

References (APA 7th Edition):

1. Ahmad, N., & Karim, N. A. (2021). The role of perioperative nurses in robotic-assisted surgery: Challenges and opportunities. *Journal of Perioperative Practice*, 31(12), 453–460. <https://doi.org/10.1177/1750458920951562>
2. Spruce, L. (2019). Implementing evidence-based practices in perioperative nursing. *AORN Journal*, 109(6), 755–764. <https://doi.org/10.1002/aorn.12740>
3. Lim, S. H., & Tan, J. (2020). Competency development in robotic surgery nursing. *International Journal of Nursing Practice*, 26(5), e12848. <https://doi.org/10.1111/ijn.12848>

Overview of Endourology & Nurse's role

Shuji Isotani, MD, PhD


Department of Urology

Juntendo University, Graduate School of Medicine

This lecture provides an overview of current endourological management of urinary stone disease and highlights the essential role of nurses in achieving safe and efficient outcomes. After briefly introducing the growing global burden of urolithiasis and regional “stone belt” patterns, I will review contemporary treatment options with a focus on ureteroscopy (URS), which has increasingly replaced shock wave lithotripsy in many countries. Key data on stone-free rates, retreatment, and complications will be summarized. I will then discuss common mechanisms of flexible ureteroscope damage, associated costs, and practical strategies for prevention, including gentle handling, optimization of irrigation and pressure, and appropriate use of single-use scopes. The session will also introduce new technologies such as pulse-modulated holmium:YAG (Moses™), thulium fiber laser, ECIRS, and vacuum-assisted systems that can improve stone clearance, visualization, and operating room efficiency. Throughout the talk, I will emphasize concrete points where nurses contribute critically—patient positioning, instrument preparation, scope protection, intrarenal pressure and infection control, and team communication—so that participants can translate these concepts into daily practice.

EXHIBITION FLOOR PLAN

Innovating Urology
INSPIRING CARE



Booth	Exhibitor
1	IDSmed
2	Calmoseptine, Inc.
3	Novartis Corporation Sdn Bhd
4	DCH Auriga (Malaysia) Sdn Bhd
5 & 10	DTG
6	Business Events Sarawak
7	Easmed Sdn Bhd
8	Dr. Reddy Laboratories (M) Sdn Bhd
9	Lifeways Sdn Bhd
11 & 12	AstraZeneca Sdn Bhd
13 & 14	Astellas Pharma (M) Sdn Bhd
15 & 16	Surgimed Tech Sdn Bhd
17	Edaptechnomed (M) Sdn Bhd
18	Orient EuroPharma (M) Sdn Bhd
1 & 20	Olympus (M) Sdn Bhd
21	Boston Scientific (M) Sdn Bhd
22 & 23	GlaxoSmithKline Pharmaceutical Sdn Bhd
24 & 25	Merck Sharpe & Dohme (M) Sdn Bhd
26 & 27	Ipsen Pharma Singaore Pte Ltd
28 & 29	Johnson & Johnson (M) Sdn Bhd
30	Zuellig Pharma Sdn Bhd
31	SYS Healthcare dn Bhd

Booth	Exhibitor
32	Transmedic Sdn Bhd
33	Pharmaniaga Sdn Bhd
34	Aspen Medical Products Malaysia Sdn Bhd
35	H&A Medical Supplies Sdn Bhd
36	Cook Asia (Malaysia) Sdn Bhd
37	QST Technologies (M) Sdn Bhd
38	Viatrix Sdn Bhd
39	Prostate Cancer Society Malaysia
40	-
41	MEGA BiO-LiFE
42	MyMedic Resources
43 & 44	Novugen Sdn Bhd
45	Ferring Sdn Bhd
46	Getz Healthcare (Malaysia) Sdn Bhd
	Biobot Surgical Pte Ltd
47 & 50	Evomedic Sdn Bhd
48	Pro Element Technology Sdn Bhd
49	IBS Medical Equipments Sdn Bhd

Hospitality Suite (Great Wall)	UMMI Surgical & Medi-Life (M) Sdn Bhd
--------------------------------	---------------------------------------



GOLD Sponsorship

Booth **S11& S12**

AstraZeneca Sdn Bhd (69730-X)

The Bousteador Tower, Level 12, No. 10, Jalan PJU 7/6, Mutiara Damansara, 47800, Petaling Jaya, Selangor, Malaysia.
 Tel: +603-7624 3888 | Fax: +603-7624 399



AstraZeneca is a global, innovation-driven biopharmaceutical business that focuses on the discovery, development, and commercialisation of prescription medicines, primarily for the treatment of cardiovascular, metabolic, respiratory, inflammation, autoimmune, oncology, infection and neuroscience diseases.

In Malaysia, we are currently one of the top pharmaceutical companies and we are committed to continued innovation, close customer relationships, people development and an ethical responsible approach to business, with an aim to make a difference to the lives of patients and the healthcare professionals.

Our Malaysia marketing company- AstraZeneca Malaysia Sdn Bhd, was established in 1981 and in 2019, the company announced a commitment to invest more than RM500 million (USD125m) in Malaysia over the next five years demonstrating a strengthening commitment towards patients, innovation and talent development in the country and rolling out new robotic and cognitive technology designed to improve efficiency and drive productivity across the Company's global operations.

In addition, a new Global Business Services hub will be equipped with cutting-edge robotic technology and automation to support financial, accounting and business services for AstraZeneca operations in the Asia Pacific region. The Robotic and Cognitive Centre will deliver 'digital disruption' in day-to-day operations, bringing greater efficiency and improving productivity that will be scaled across global operations using Robotic Process Automation, mimicking human actions by performing repetitive rules-based tasks across multiple applications.

AstraZeneca Malaysia marketing company's vision is to push the boundaries of science to deliver life-changing medicines that addresses unmet medical needs in non-communicable diseases such as Cardiovascular, Diabetes, Renal Diseases and Cancer as well as Respiratory Illnesses.

We are aiming to treat, prevent, modify and in the future, even cure. It is only by enhancing our understanding of disease biology and uncovering new ways of targeting the drivers of disease that we will create the next generation of therapeutics across our main therapy areas.

Beyond accelerating our innovative pipeline to patients, AstraZeneca Malaysia partners with local stakeholders in Malaysia to increase healthcare access, stimulate innovation and improve outcomes through 'beyond the pill' approaches.

Booth **S13 & S14**

Astellas Pharma Malaysia Sdn Bhd

Pavilion Damansara Heights, Unit 9.02 and 9.03, Level 9, Corporate Tower 2,
 3, Jalan Damansara, Pusat Bandar Damansara, 50490 Kuala Lumpur.
 Tel: +603-2022 6999 | Fax: +603-2022 6988 / 977 | www.astellas.com



Astellas Pharma is a global pharmaceutical company dedicated to improving the health and well-being of people worldwide. Headquartered in Japan, Astellas focuses on the discovery, development, and commercialization of innovative therapies in areas such as oncology, urology, immunology, and neurology. The company is driven by cutting-edge research and technology, striving to address unmet medical needs and provide patients with life-changing treatments. With a commitment to sustainability and ethical business practices, Astellas is a leader in advancing healthcare solutions across the globe.

Booth **S21**

Boston Scientific (Malaysia) Sdn Bhd

Suite 3-3, Level 3, UOA Corporate Tower Avenue 10, The Vertical, Bangsar South City, No 8, Jalan Kerinchi, 59200 Kuala Lumpur, Malaysia
 Tel: +603-2858 9880 | Fax: +603-2389 9866 | www.bostonscientific.com



Boston Scientific is dedicated to transforming lives with less-invasive technologies engineered to diagnose and treat a wide range of medical conditions. We're dedicated to collaborating with healthcare professionals to develop a broad portfolio of meaningful innovations that improve outcomes, reduce costs, increase efficiencies and—most importantly—help more people in more places around the world live longer, healthier lives. Our work in health care is about addressing patients' critical needs, expanding access to care and helping improve outcomes so people can lead longer, better lives, by helping physicians diagnose and treat complex cardiovascular, vascular, digestive, oncological, neurological, urological and pelvic health diseases and conditions.



GOLD Sponsorship



Booth S24 & S25

**Eisai (M) Sdn Bhd**

Unit 701D, Level 7, Tower D, Uptown 5, 5, Jalan SS 21/39, Damansara Utama, 47400 Petaling Jaya, Selangor
Tel: +603-7732 0380

A pharmaceutical subsidiary of Eisai Co., Ltd., Eisai Malaysia celebrated its golden jubilee in 2019 to mark the corporation's presence and growth in the country since 1969. Inspired by the history and expansion of its parent company in Japan, Eisai Malaysia continues to champion and advocate for universal access to innovative medicines.

Eisai Malaysia is steadfast in its commitment to be the pioneering hmc company in the nation, firm in the belief that the people's health cannot be approached as a mere statistic, but as a holistic experience that is capable of transforming communities, beyond healing the individual patient. To that end, Eisai Malaysia is indebted to the selfless and unsung heroes who have helped to grow the company's influence and outreach, allowing previously untapped communities to benefit its scientific endeavours.

Eisai Malaysia looks forward to continuing its strategic collaborations with stakeholders and partners, including healthcare providers, to fulfil its corporate objective for the next 50 years and beyond.

**Merck Sharp & Dohme (Malaysia) Sdn Bhd**

B-22-1 & B-22-2, The Ascent Paradigm, No 1, Jalan SS7/26A, Kelana Jaya, 47301 Petaling Jaya, Selangor, Malaysia
Tel: +603-7499 1600 | www.msdl.com

Merck Sharp & Dohme (MSD) Malaysia is a leading research-intensive biopharmaceutical company committed to saving and improving lives. As a subsidiary of Merck & Co., Inc., with headquarters at Rahway, NJ USA, Merck is known as MSD outside of the US and Canada. The company specializes in discovering, developing, manufacturing, and marketing innovative healthcare products to address critical health challenges and enhance patient outcomes.

Booth S22 & S23

**GlaxoSmithKline Pharmaceutical Sdn Bhd**

HZ.01, Horizon Penthouse, 1 Powerhouse
1, Persiaran Bandar Utama, Bandar Utama, 47800 Petaling Jaya, Selangor, Malaysia

GlaxoSmithKline (GSK) – GSK plc, is a global biopharma company, headquartered in London, England. We operate in over 70 countries and employ more than 70,000 people globally. GSK's purpose is to "unite science, technology and talent to get ahead of disease together. We prioritise innovation in specialty medicines and vaccines to prevent and treat disease. .GSK also focuses on the science of the immune system and advanced technologies, investing in 4 core therapeutic areas (respiratory, immunology and inflammation; oncology; HIV; and infectious diseases) to impact health at scale. GSK aims to positively impact on the health of more than 2.5 billion people by the end of the decade. GSK Malaysia started its operations in October 1958 and has been supporting the strengthen the healthcare of Malaysians for over 66 years. The company also has its shared services centre, GSK Business Services Centre Sdn Bhd, that began operations in 2008 as a APAC regional hub. GSK's Pharmaceutical Division and Shared Services have a combined workforce of more than 400.

Booth S26 & S27

**Ipsen Pharma Singapore Pte Ltd**

Unit J.08, G.016, The Square, Common Ground Jaya One
72A, Jalan Profesor Diraja Ungku Aziz, Seksyen 13, Petaling Jaya, 46200 Selangor, Malaysia.

Ipsen is a French leading global mid-size biopharmaceutical company headquartered in Paris, France focusing its efforts where unmet medical needs are greatest. Ipsen develops and commercializes innovative medicines in three key therapeutic areas - Oncology, Rare Disease and Neuroscience. We have over 5000 employees worldwide and our medicines are registered in more than 100 countries, with direct commercial presence in over 30 countries. Ipsen has 4 global R&D hubs and 3 pharmaceutical development centres around the world.



GOLD Sponsorship



Booth S15 & S16

**Surgimed Tech Sdn Bhd**

No 78B, Jalan Teknologi 3/9, Bistari De Kota, Kota Damansara, 47810 Petaling Jaya, Selangor
Tel : +603-6150 4046

As a primary focus, we operate as a distributor of urological instruments, offering technical support and services for surgical appliances. This includes leasing and renting lasers to both government and private hospitals across Malaysia.

Our utmost priority lies in delivering exceptional services to our patients, accomplished through our team of professionally trained technicians proficient in handling surgical appliances and urological services. We hold our customers in high regard, striving to deliver outstanding products and services consistently.

Our Vision

Being a trailblazing leader in urology instruments, we aim to empower professionally with inventive and state-of-the-art solutions that enhance the lives of patients.

Our Mission

Innovation and Research: We commit ourselves to continuous research and development, harnessing the latest technologies and ideas to create advanced urological instruments that enhance medical outcomes and patient experiences.

Quality and Precision: We uphold the highest standards of quality, ensuring that our urology instruments are precise, reliable, and safe for medical professionals and patients alike.

Customer-Centric Approach: Our focus remains on understanding and fulfilling the unique needs of our customers, building strong relationships based on trust and exceptional service.

Global Reach: We aim to expand our reach globally, collaborating with healthcare providers and institutions around the world to make our urology instruments accessible to all in need.



SILVER Sponsorship



Booth S36

**Cook Asia (Malaysia) Sdn Bhd**

Unit 1602, Level 16, Uptown 1, No. 1, Jalan SS21/58, Damansara Utama, 47400 Petaling Jaya, Selangor Malaysia
Tel: +603-7669 3889 | Fax: +603-7669 3898 | Email: CS.Malaysia@CookMedical.com

A patient-first philosophy and innovative spirit have helped Cook become a leader in urology. With a focus on stone management and prostate health, we pride ourselves on providing quality solutions without compromise. By uniting with healthcare professionals around the world, we're committed to advancing treatment and making a difference, together.

以患者为先的理念和创新精神使库克成为了泌尿外科的领导者之一。我们专注于结石管理领域，提供不折不扣的高质量解决方案，并引以为傲。透过与全球的医疗专家合作，我们致力于联手促进治疗效果，并为泌尿外科专业带来改变。

(我们相信医生与产业合作是提供更好的医疗的关键。这，是我们的核心信念。我们的教育和培训计划鼓励共享作业规范和学习使用库克的创新产品的新技巧。)

Booth S5 & S10

**Device Technologies**

3A-03, Wisma Mont Kiara, , 1, Jalan Kiara, 50480 Kuala Lumpur, Malaysia
Toll-Free Number 1800 812 011 | Phone: +603-2779 2586 | Email: customers.my@devicetechnologies.asia

Introducing Device Technologies

For over 30 years, Device Technologies has been dedicated to improving patients' lives through delivering some of the world's most advanced medical technology and services.

More about Device Technologies

Representing over 200 trusted brands, supported by a highly experienced, dynamic team of over 1,100 staff across Australia, Indonesia, Malaysia, New Zealand, Philippines, Singapore, Thailand and Vietnam - Device Technologies is committed to supporting healthcare professionals to enhance patient outcomes from consult to recovery, and beyond. By nurturing strong relationships between manufacturers and healthcare professionals, the organisation ensures a steady pipeline of innovation, clinical support for customer readiness, and ongoing excellence in patient care.

What can you expect from Device Technologies?

As a leader in the medical technology industry, Device Technologies provides some of the world's most advanced medical technology, with innovation, customer needs, and patient care at the heart of its values. All products distributed by Device Technologies are compliant with quality and regulatory requirements, with in-servicing and ongoing support provided as part of the trusted relationship between Device Technologies and its customers.

Pioneering possibility is at the epicenter of what we do. We strive for innovation, collaboration, taking ownership, conducting good business, and championing our customer in everything we do.

From the consult room to the operating theatre, the Device Technologies vision is to enable superior patient outcomes. This is achieved by connecting healthcare professionals with leading-edge medical technology, supporting the continuum of care from consult to recovery.

Device Technologies ensures that leading technology is delivered into the most capable hands. By fostering strong relationships between manufacturers and healthcare professionals, the organisation drives enhanced outcomes through clinical and specialised training, technical servicing, and ongoing customer support.



SILVER Sponsorship



Booth S47 & S50

Evomedic Sdn Bhd (Co.No. 201601027096 (1198035-D))

HQ Office: Lot No. H-05-02, Block H, Aeropod Commercial Centre Phase 2A, Jalan Aeropod, Off Jalan Kepingan, 88200 Kota Kinabalu, Sabah.
Tel / Fax : +6088-276 923



Petaling Jaya Branch : C-G-03 & C-1-03, Block C, Oasis Corporate Park, No.2, Jalan PJU 1A/2, Ara Damansara, 47301 Petaling Jaya, Selangor.
Tel / Fax : +603- 7832 2368 | Website : my-evomedic.com

Evomedic Sdn Bhd is a Malaysia-based company committed to empowering healthcare professionals by delivering innovative, high-quality medical solutions at optimal price-performance. We specialize in supporting both private and public healthcare sectors with advanced technologies and comprehensive services.

Our product portfolio focuses on minimally invasive surgery, featuring leading brands such as Bonss Medical (Radio Frequency Plasma Surgical Systems), Mindray Medical (endoscope camera & laparoscopic instruments), Macrolux (wide range of disposable endoscope) and Veol Medical (contained tissue extraction systems).

Beyond supplying equipment, Evomedic offers full-cycle support: sales, rental, preventive maintenance, and hands-on training. We stand ready to provide on-site demonstrations and consultations to help clinicians realize the full potential of their tools.

At the heart of everything we do is our tagline: "We Evolve With You" — because the medical field never stands still, and neither do we.

Booth S28 & S29

Johnson & Johnson Sdn Bhd

Level 8, The Pinnacle, Persiaran Lagoon, Bandar Sunway, 46150 Petaling Jaya, Selangor.



Johnson & Johnson is committed to redefining healthcare: connecting the best of Health&Care for every provider, for every patient, for everyone.

Johnson & Johnson Innovative Medicine is leading where medicine is going. Patients inform and inspire our science-based innovations, which continue to change and save lives. With rigorous science and compassion, we confidently address the most complex diseases of our time and unlock the potential medicines of tomorrow. Therapeutic areas include Oncology, Immunology, Neuroscience, Cardiovascular, Pulmonary Hypertension, and Retina. Specifically for Oncology, one of our commitments is to improve patients diagnosed with genitourinary cancers.

Johnson & Johnson MedTech segment strives to provide that the next generation of smarter, less invasive, and more personalized medical technology treatments to tackle the most pervasive and complex health challenges for people around the world. Focus areas include Orthopedics, Surgery, Cardiovascular and Vision.

Booth S19 & S20

Olympus (Malaysia) Sdn Bhd

Unit T2-L05-1, PJ33, No. 3, Jalan Professor Khoo Kay Kim, Seksyen 13, 46200 Petaling Jaya, Selangor, Malaysia.
Office Tel: +603-7650 8990 | www.olympus.com.my



Founded in 1919, **Olympus** is a global leader in **medical technology and optical precision**. Guided by our brand philosophy "**True to Life**", Olympus is committed to helping healthcare professionals deliver the highest standards of care through exceptional visualization and minimally invasive innovation.

Our Focus

Olympus designs and manufactures **endoscopic, laparoscopic, and surgical imaging systems** that enable accurate diagnosis and effective treatment across gastrointestinal, urology, respiratory, and general surgery specialties. Our advanced medical solutions empower clinicians to see with clarity, act with precision, and improve patient outcomes.

Commitment to Healthcare Excellence

With a mission to make people's lives *healthier, safer, and more fulfilling*, Olympus continues to invest in research, education, and service excellence. We work closely with healthcare professionals to deliver reliable, innovative, and clinically proven solutions that meet evolving medical needs.

Presence in Malaysia

Olympus (Malaysia) Sdn Bhd supports healthcare institutions nationwide through a dedicated team providing sales, service, and clinical support. We are committed to ensuring timely technical assistance, continuous training, and dependable partnership for our customers throughout Malaysia.

True to Life. Olympus.





SILVER Sponsorship



Hospitality Suite
Great Wall,
Pullman Kuching

**Medi-Life (M) Sdn Bhd**

No. 10, Jalan Pendaftar U1/54, Kawasan Perindustrian Temasya, 40150 Shah Alam, Selangor.
Tel: +603-5569 2699 | Fax: +603-5569 3299 | Email: info@medi-life.com.my

We are distributor of medical equipment and devices in Malaysia, providing high quality, state of the art medical advances to leading hospitals in Malaysia.

Our corporate slogan, "When Quality Healthcare Matters" simply means that we've committed ourselves to making a positive difference in the lives of patients and those who care for them, by helping our customers deliver safer, efficient and effective care.

Medi-Life started with a team of four personnel and one agency line in year 2008 and with further acquiring of agency lines, today we have staff strength of over 80 people working from five strategically located offices across Malaysia and total of 31 agency lines. With such a wide and comprehensive range of products we hope to provide our customers a one-stop center of total solution.

Hospitality Suite
Great Wall,
Pullman Kuching

**UMMI Surgical Sdn Bhd**

No.10 (1st Floor), Jalan Pendaftar U1/54, Temasya Industrial Park, 40150 Shah Alam, Selangor Darul Ehsan, Malaysia
Tel: +603-5569 6799 | Fax: +603-5569 8799 | Email: info@ummisurgical.com.my

About Us

UMMI Surgical Sdn Bhd is the exclusive distributor for Karl Storz Endoscopy in Malaysia. We commenced business activities in 2009, upon our appointment by Karl Storz. Karl Storz (www.karlstorz.com) produces the highest quality rigid and flexible endoscopes, instruments and equipment across 18 different medical specialties and is the world's most recognized brand for minimally invasive surgery products.

Our Values

We are responsible to our customers. We take responsibility to ensure the products are supplied in the same condition they left the factory and the end users are able to use them to achieve the desired results they're intended for, surgically or medically; to benefit the patients. We commit ourselves to provide the support needed for the optimum utilization of the products.

We are responsible to our people. They are our greatest assets. Taking pride in what we do, each and every member of our team contributes to deliver values to our customers. UMMI Surgical provides solutions, achieves results and earns reputation via its people. We take great effort to provide comfortable working environment and ensure the well-being of our people. We continuously invest in leadership and management programmes to nurture, develop and empower our people. We believe when people feel they belong and are secured; they consistently produce quality works and act in the best interest of the company.

We are responsible to our principal. As a partner, we are committed to market the products in the most responsible manner and we believe we deliver the best value to the customers by working closely with our principal.

Our Motto - Making A Difference

At UMMI Surgical, we strive to provide the best solutions for our customers. This can be achieved by delivering excellent products with the commitment and professionalism of our people in marketing; pre-sales and after sales services; as well as technical support. By giving our best in everything we do, we believe we can make a difference in helping our customers provide the best patient care.

UMMI Surgical and Karl Storz are committed to; and heavily support the training and educational activities of surgical and medical personnel in the area of endoscopy. Within our own capacity, we help to enhance and facilitate the learning activities. By working in partnership with our customers, we hope to make a meaningful contribution towards achieving better patient outcome.

Our Milestones

2009 – Commenced business from a rented shop lot at Ara Damansara

2013 – By November, moved into our very own premise of approximately 22,000 square feet at Temasya Industrial Park, occupying half of the space we share with Medi-Life Sdn Bhd

EXHIBITORS PROFILE

Other sponsorship



Booth S34

Aspen Medical Products Malaysia Sdn Bhd

Unit 1302A, Level 13A, Uptown 1, 1 Jalan SS21/58, Damansara Uptown, 47400 Petaling Jaya, Selangor, Malaysia
Tel: +603-7733 9795 | Direct Tel: +603-7733 0368 | Mobile: +6016 4425942 | www.aspenpharma.com



Aspen Malaysia is a subsidiary of Aspen Pharmacare Holdings, a South African-based multinational pharmaceutical company with a 170-year heritage. Aspen focuses on marketing and manufacturing a broad range of post-patent, branded medicines and domestic brands covering both hospital and consumer markets in more than 115 countries. In Malaysia, Aspen offers branded pharmaceutical products in various therapeutic categories, which includes urology, anaesthetics, thrombosis, critical care medications, high potency and cytotoxic drugs. Aspen is committed to act with integrity and aspired to improve the health and quality of life of patients.

Booth S2

Calmoseptine Inc.

16602 Burke Lane, Huntington Beach, CA 92647-4536
Phone: (714) 840 - 3405 | Fax: (714) 840 - 9810 | Email: Info@Calmoseptine.com | Website: calmoseptineointment.com
Facebook: <https://www.facebook.com/Calmoseptine/>
LinkedIn: <https://www.linkedin.com/company/calmoseptine-inc>
Instagram: <https://www.instagram.com/calmoseptineinc/>
Contact: Greg Dixon, CEO

**CALMOSEPTINE® OINTMENT**

Calmoseptine® Inc. promotes Calmoseptine® Ointment for the prevention and treatment of skin irritations from moisture such as urinary and fecal incontinence. It is also effective for irritations from perspiration, wound drainage, fecal & vaginal fistulas and feeding tube site leakage. Calmoseptine® Ointment temporarily relieves discomfort and itching. Free samples at our booth!

Booth S4

DCH Auriga (Malaysia) Sdn Bhd – A Dah Chong Hong Company

Lot 6, Persiaran Perusahaan Seksyen 23, Kawasan Perusahaan Shah Alam, 40300 Shah Alam, Selangor Darul Ehsan, Malaysia
Tel: +603-5541 7748 | Fax: +603-5542 1486



Auriga is an Asian-based integrated market management provider specialising in healthcare. We aim to connect the world's leading healthcare and life sciences companies to care providers and patients across Asia with a comprehensive range of responsible and effective market management solutions.

For over 50 years, we've helped our partners bring essential pharmaceutical and life science offerings to Asia with ethical integrity, partnership and transparency. Offering both commercial and logistics solutions, Auriga has operations in Hong Kong, Macau, mainland China, Singapore, Thailand, Indonesia, Brunei, Malaysia, Vietnam and the Philippines. In alignment with our mission to enrich lives with quality care, we distribute more than 500 brands at over 10,000 points of sale.

In November 2017, LF Asia was rebranded as DCH Auriga to signify a new chapter for the company with an exclusive focus on the healthcare industry. Our name is inspired by a constellation known in both the Western and Eastern traditions as 'the charioteer'. It symbolises our commitment to help our principals navigate market complexities as they explore new opportunities. Auriga represents our mission of stewardship, expansion and growth

Booth S8

Dr. Reddy's Laboratories Malaysia Sdn Bhd

Unit No. SO-29-07 and SO-29-08, Menara 1, Strata Office, No. 3, Jalan Bangsar, KL Eco City, 59200 Kuala Lumpur, Malaysia.



We started in 1984 with a modest investment and a bold vision. We were the first Asian pharma company outside Japan to list on the New York Stock Exchange in 2001. We are committed to the highest standards of compliance, ethics and quality in every activity that we undertake.

Our products and services are spread across our core businesses of Active Pharmaceutical Ingredients (API), generics, branded generics, biosimilars and over-the-counter pharmaceutical products around the world. We work towards meeting unmet patients' needs in the areas of gastro-enterology, cardiovascular, diabetology, oncology, pain management and dermatology. We are investing in businesses of the future including drug discovery, clinically differentiated assets and digital healthcare.

For four decades, Dr. Reddy's Laboratories has stood for advancing healthcare through access, affordability and innovation. Our work has been guided by our core tenets of deep science, progressive people practices and robust governance. 'Good Health Can't Wait' has become a movement and call to action for all of us, and good health encompasses people, planet and patients.

Today, with research and development centres, manufacturing facilities and commercial presence across the globe, we serve over half a billion patients worldwide. We are grateful for the trust our patients and stakeholders have had in us throughout our journey. We will continue to work on strengthening our core further and building the future of healthcare as we aim to touch the lives of over 1.5 billion patients by 2030.

EXHIBITORS PROFILE

Other sponsorship



Booth S17

**Edaptechnomed (M) Sdn Bhd**

No. 16 (1st Floor) USJ 10/1B, Taipan Triangle, Subang Jaya, 47620 Selangor, Malaysia
Tel: +603-5634 9335 | Fax: +603-5634 9733

Edaptechnomed (M) Sdn Bhd is a specialized urology equipment company focusing on stone and prostate management.

Stone Management:

- Surgical Lasers: Holmium and TFL lasers from Quanta System, including Litho 30W, Litho 35W, Litho EVO, Cyber Ho (60W, 100W, 150W), Fiber Dust (TFL) and Fiber Dust Pro (TFL Pro).
- Irrigation Systems: Ureteroscopy irrigation solutions like Peditrol or Smart Bulb from Wismed.

BPH (Benign Prostatic Hyperplasia) Management:

- Surgical Lasers: Holmium and Thulium lasers from Quanta System, such as Fiber Dust, Fiber Dust Pro, Cyber TM Family, and Cyber Ho (60W, 100W, 150W).

Single Use and Reusable Prostate Morcellator

- Quanta System and Hawk.

Prostate Cancer Management:

- Detection: Micro-ultrasound fusion device (Exact Vu) from Exact Imaging.
- Therapy: Focal therapy solutions, including Focal One from EdapTMS.

Booth S7

**Easmed**

Level 6 Suite 6.01 & 6.02 Persiaran Kewajipan USJ 1, 47600 UEP Subang Jaya, Selangor Darul Ehsan
Office General Line: 03-8025 9328 | www.easmed.com

Easmed is a leading medical device distributor specialising in the fields of ENT, General Surgery, Urology, Sleep Medicine, Respiratory & Critical Care in South-East Asia.

We are proud to be the partner of choice in raising the standard of care. Our current distribution network is across Singapore, Malaysia, Philippines, Thailand and Indonesia.

Booth S45

**Ferring Sdn Bhd**

21-6, Block B, Jaya One, No. 72-A, Jalan Profesor Diraja Ungku Aziz, 46200 Petaling Jaya, Selangor Darul Ehsan, Malaysia
Phone: 03-7960 3032 | www.ferring.com

Ferring Pharmaceuticals a privately owned, research-driven, specialty biopharmaceutical group committed to building families and helping people live better lives. We are leaders in reproductive medicine with a strong heritage in gastroenterology and urology, and are at the forefront of innovation in uro-oncology gene therapy. The company was founded in 1950 and is headquartered in Saint-Prex, Switzerland. Ferring employs more than 7,000 people worldwide and market its medicines in over 100 countries. Ferring Sdn Bhd is based in Petaling Jaya, Selangor, Malaysia and employs around 20 people. For more information, please contact 603-7960 3032.

Booth S46

**Getz Healthcare (Malaysia) Sdn Bhd**

Unit 15-3 & 15-3A, Oval Damansara Tower, 685, Jln Damansara, Taman Tun Dr Ismail, 60000 Kuala Lumpur, Wilayah Persekutuan Kuala Lumpur

Getz Healthcare Malaysia has been a trusted partner in the medical industry for nearly 50 years, delivering innovative healthcare solutions across Urology, Interventional Radiology, Cardiology and Surgery. Backed by ISO9001:2015 and GDPMD certifications, our passionate team provides exceptional clinical and technical support to hospitals nationwide.

BIOBOT**Biobot Surgical Pte Ltd**

79, Ayer Rajah Crescent #04-05, Singapore 139955
Tel: +65-6351 1861 | www.biobotsurgical.com

At Biobot Surgical, we are dedicated to redefining the standard of care in urology through technological innovation. Our flagship product, the iSR'obot Mona Lisa system, arms urologists with cutting-edge robotic precision and enhanced visualization for percutaneous transperineal procedures. And together with urologists we've completed over 25,000 procedures across the globe, including the US, China, Australia, Europe, and the Asia Pacific. Our focus remains on expanding the applications and accessibility of our technology, ensuring that both surgeons and patients worldwide benefit from the precision and care they deserve.

EXHIBITORS PROFILE

Other sponsorship



Booth S35

**H & A Medical Supply Sdn Bhd**

CT-05-11 Corporate Tower Subang Square, Jalan SS15/4G, 47500 Subang Jaya, Selangor, Malaysia
Tel: +603-5636 6732

H&A Medical Supply Sdn Bhd was incorporated on JAN 2007 and located at Subang Jaya, Selangor.

H&A started with some Cardiology and Radiology accessories, and focused on interventional devices. The company then extended the service into Shock Wave Lithotripsy, Imaging Equipment, and Nuclear Medicine accessories.

H&A is strongly committed to provide quality products and after sales service to the customers

Booth S49

**IBS Medical Equipments Sdn Bhd**

Headquarters: No.7-G, 3rd Mile Square Business Center, Old Klang Road, 58100 Kuala Lumpur.
Tel: +603-79714221 | www.ibsmedic.com

At IBS Medic, our vision is to consistently bring cutting-edge innovative products to the urology community in Malaysia. Supported by a dedicated and highly trained team, we are committed to delivering world-class service and solutions.

In 2025, we introduced the AI-enabled Fusion Ultrasound Biopsy System, marking a significant leap forward in diagnostic precision. Looking ahead to 2026, we are excited to expand our portfolio with the introduction of an advanced Robotic Surgical System and Blue Laser System, among other groundbreaking products.

Our team is expertly trained to understand and meet the unique requirements of our customers. We pride ourselves on providing exceptional support and service. We look forward to the opportunity to partner with you and provide the world-class solutions your practice deserves.

Booth S1

**IDS Medical System (M) Sdn Bhd**

8 Jalan Pensyarah U1/28, Hicom Glenmarie Industrial Park 40150, Shah Alam, Selangor, Malaysia
Tel: +603-5022 5225 | Fax: +603-5022 5335 | moc.demsdi@ofnisym

The IDS Medical Systems Group ("idsMED Group") is a leading integrated medical supply chain solutions company in ASEAN for almost a decade. It represents over 200 global medical brands in equipment and medical consumables, focusing on various specialty divisions including Intensive Care, Infection Control, Surgical Workplace, Diagnostic Imaging, Patient Support System, Cardiovascular, O&G and Peri-natal, among others.

As a member of Fung Investments, idsMED Group has offices in the six markets - Singapore, Malaysia, Indonesia, the Philippines, Thailand, and Vietnam. It provides a comprehensive distribution and value-added service network to over 10,000 healthcare facilities, including government and private hospitals, day surgery centres, specialist and primary care clinics, laboratories and nursing homes.

With 1,800 employees, including 800 professionally qualified medical and sales personnel and over 300 skilled biomedical engineers, idsMED offers a one-stop solution for marketing and sales, biomedical engineering services, clinical care, reliable product management and logistics services.

Booth S9

**Lifeways Sdn Bhd** (703061-D)

5, Jalan Permata 2A/KS9, Taman Perindustrian Air Hitam, 41200 Klang, Selangor, Malaysia.
Tel: +603-3123 1277 | Fax: +603-3123 1977 | www.lifeways.com.my

Lifeways Sdn Bhd is committed to advancing urological care through innovative and reliable solutions.

Our product portfolio includes Vathin single-use ureteroscopes and cystoscopes, as well as urological accessories such as ureteral access sheaths, stone removal baskets, stents, dilators, biopsy devices and urological drapes.

At Lifeways, we take pride in providing responsive customer service and reliable local support, ensuring a seamless experience for our hospital and clinical partners.

EXHIBITORS PROFILE

Other sponsorship



Booth S41

**BiO-LiFE Marketing Sdn Bhd** (167808-V)

B-28-02, The Ascent, Paradigm, No.1, Jalan SS 7/ 26A, Kelana Jaya,, 47301 Petaling Jaya, Selangor.
Tel : +603-7499 7999 | Fax: +603-7882 6388

BiO-LiFE Marketing is a healthcare company engaged in wellness with 32 years of existence in Malaysia. It has an able team of Nutritionists, Biochemists, Food technologists and Microbiologists that help bring relevant products to consumers.

BiO-LiFE Marketing became a part of Mega Lifesciences since its acquisition in Nov 2016. Mega Lifesciences is a leading pharmaceutical and nutraceutical company headquartered in Bangkok and publicly listed since 2014. Mega is actively involved in helping millions of people have access to safe, effective, world class quality nutritional & herbal supplements, OTC and ethical products.

Established in 1982, Mega Lifesciences is engaged in manufacturing, marketing, selling and distributing Medicines through its own offices and also through an extensive distributor network. Its world class manufacturing standards is backed by approvals from Thailand FDA, Australia TGA & German GMP

Booth S42

**MyMedic Resources**

No. 16, 2, Jalan Utama Suria Tropika 1, Taman Suria Tropika, 43300 Seri Kembangan, Selangor
Tel: +603-8958 5514 | Fax : +603-89958 5515 | www.mymedicresources.com

My Medic Resources (MMR), established in 2007, is a trusted name in advanced medical technology across Malaysia and Brunei. In partnership with EMS Switzerland and Zhuhai Seesheen Medical Technology Co., Ltd., MMR delivers cutting-edge urology and laser solutions, including the Thulium Fiber Laser, Holmium Laser, Trilogy, LithoClast, and a complete range of urology scopes for RIRS, both reusable and disposable. With a strong focus on innovation, reliability, and customer care, MMR is committed to empowering healthcare professionals with world-class technologies that elevate clinical performance and improve patient outcomes.

Booth S3

**Novartis Corporation (M) Sdn Bhd**

Level 18, iMAZIUM, No 8 Jalan SS 21/37, Damansara Uptown, 47400 Petaling Jaya, Selangor
Enquiries: +603-7682 7777

Novartis has a long heritage and legacy in Malaysia. Established in 1971, we are a leading multinational company employing close to 700 associates who work in the Novartis International division and Novartis Corporate Center, Kuala Lumpur. Through our over 50-year presence in Malaysia, Novartis Malaysia continues to deliver on its corporate purpose of reimagining medicine to improve and extend the lives of over 32 million Malaysians.

In 2022, Novartis Malaysia was recognized as Sponsor of the Year by Clinical Research Malaysia for initiating 24 new clinical trials. We also have a proven track record of expanding access to our innovative medicines in private or public via collaborations with the Ministry of Health. Through these collaborations, Novartis has succeeded in touching the lives of more than 1.7 million Malaysian patients.

Novartis Malaysia's office is located in the new cutting-edge building called Plaza Imazium in Damansara Utama, Petaling Jaya. Novartis Malaysia occupies 2 floors and was one of 20 offices in Malaysia to be LEED Gold certified and the first office to be WELL Silver certified.

EXHIBITORS PROFILE

Other sponsorship



Booth S43 & S44

Novugen Pharma Sdn Bhd

3, Jalan Jururancang U1/21, Hicom-Glenmarie Industrial Park, 40150 Shah Alam, Selangor



Novugen is a wholly owned subsidiary company of a UAE based group, SciTech International. With over 30 years of experience in the healthcare industry, the company is equipped with vast and successful experience of venturing into strategic healthcare businesses and development of world class healthcare facilities around the globe. Novugen's passion for science, bold global strategy and wealth of international experience prepared us to respond to complex challenges of bringing hard-to-source and technology-intensive pharmaceutical products to the market.

Novugen specializes in niche and difficult to formulate generics for all therapeutic areas of general and oncology medicines while meeting stringent global quality standards. With vertically integration from Active Pharmaceutical Ingredients (API) to Finished Products R&D and manufacturing based in Malaysia, it gives us greater control over the supply chain. Malaysia is also home to our state-of-the-art manufacturing facilities, designed by globally renowned European pharmaceutical engineering firm following stringent regulatory requirements by authorities across the globe including USFDA, EMA, PIC/S and WHO.

We are the first USFDA approved pharmaceutical company in Malaysia and the Only in Southeast Asia with manufacturing facilities focusing on oral solid dosage forms for general medicines and highly potent Oncology drugs. The accreditation by the U.S. federal agency positions us as the first pharmaceutical company in the country to manufacture high-quality medicines locally in Malaysia for the U.S. market. Our manufacturing facilities are also Halal compliant, a reflection of our commitment to respond to the increasing demand of Halal products in the local market and a testament to our purpose of serving the burgeoning demand of Halal products globally.

Novugen enhances in achieving the desired quality of our products with systematic Quality by Design (QbD) approach. With our robust team of professionals and scientists, advanced R&D centre and USFDA Approved manufacturing facilities in Malaysia, we are committed to ensure early access of high-quality products that lack robust generic alternatives due to their complexity. We strive to strengthen the accessibility of affordable and global quality standard products in Malaysia with same efficacy to medicines exported to the U.S.

Novugen's business outlook targets a wider market penetration globally. Our focus is on ASEAN, CIS, GCC, Africa & LATAM regions and expanding through distributor channels in the U.S., Europe and Canada markets. Today, Novugen is present globally with 5 offices worldwide, including, Malaysia, the U.S., Uzbekistan, UAE, and Pakistan. In 2030, we are targeting to enter the global market of 89 countries worldwide, covering all continents.

The people behind Novugen are united to achieve one common vision to be the largest and fastest growing pharmaceutical company in Southeast Asia by 2030, competing in global markets. Our aim is to make an impact on Malaysia's economy, being a self-sufficient nation, capable to supply quality medications locally and increasing the country's power to export. Devoted to the cause, we hold the highest standards of ourselves, finding ways to serve patients locally and all over the world with life-changing medicines.

Booth S18

Orient Europharma (M) Sdn BhdE-08, Garden Shoppe, One City, Jalan USJ 25/1C, 47650 Subang Jaya, Selangor Darul Ehsan, Malaysia
Tel: +603-8081 6637 | Fax: +603-8081 8137 | Email: oemsb@mail.ope.com.tw

Orient Europharma

OEP COMPANY INTRODUCTION:

Founded in 1982, Orient EuroPharma (OEP) became officially listed in the Taiwan Exchange in 2003. In the beginning, the Company was a prescription drug distributor, but has now become a full-scale, multinational pharmaceutical company. The core competencies of the Company not only include pharmaceutical innovation, R&D, manufacturing, sales and clinical trials, but has significantly increased the Company's operational efficiency through vertical integration to provide customers with more complete services.

From the very beginning of its establishment, OEP has focused on creating the subsidiary companies to develop and manufacture new drugs to meet real human needs. Moreover, the Company is committed to providing products and services that are valuable and unique. Currently, OEP has three major business focuses on prescription medicines, nutriceuticals and anti-aging, respectively. Each business focus is not only committed to developing its individual brand, but also continues to seek cooperation opportunities with internationally renowned pharmaceutical companies.

Since 2000, OEP has successively established overseas subsidiaries in Singapore, Malaysia, Hong Kong and the Philippines. In 2006, the Company established subsidiaries in Mainland China, and is steadily cultivating the Asia-Pacific market and gradually reaching the goal of becoming a benchmark enterprise in the Asia Pacific.

The Company's core value - **Through Integrity, United We Achieve and Be Remarkable**, is manifested in every detail of the team effort to innovate and grow together.

EXHIBITORS PROFILE

Other sponsorship



Booth S33

**Pharmaniaga Berhad**

No 7, Lorong Keluli 18, Kawasan Perindustrian Bukit Raja Selatan, Seksyen 7, 40000 Shah Alam, Selangor
Tel: +603-3342 9999 | Fax: +603-33442222 | www.pharmaniaga.com

Established in 1994, Pharmaniaga has grown into Malaysia's largest listed integrated pharmaceutical group, with operations that span the entire pharmaceutical value chain, from research and development to the manufacturing of generic medicines, as well as logistics, distribution, sales, and marketing.

In 2021, Pharmaniaga made history as the first Malaysian pharmaceutical company to undertake the fill-and-finish manufacturing of a human vaccine.

Building on this milestone, the Group achieved another national breakthrough in 2024 with the completion and launch of Malaysia's first locally owned insulin and vaccine manufacturing facilities at Pharmaniaga LifeScience Sdn Bhd in Puchong, Selangor.

In the urology segment, Pharmaniaga offers a comprehensive portfolio to meet patients' needs. Iqnyde (Sildenafil) remains the leading choice based on dosing units, reflecting strong patient trust and preference. We have also recently launched Liberez (Tadalafil), providing greater treatment flexibility. Looking ahead, the upcoming Avorna (Dutasteride) and Avorna Duo (Dutasteride + Tamsulosin) set to launch in January 2026 will further strengthen our commitment to advancing urology care.

Booth S48

**Pro Element Technology Sdn Bhd** (906780-M)

18-34-A3, Persiaran Gurney, Gurney Tower, 10250 Georgetown, Penang, Malaysia.
Tel: +604-226 3286 | Fax: +604-227 3286 | Email: info@pro-element.com.my | www.pro-element.com.my

About Us

Established in July 2010, Pro Element Technology Sdn Bhd is a Penang-based medical device distributor with a strong nationwide sales and marketing network. The company holds a valid Establishment License under the Medical Device Authority (MDA) and is certified in Good Distribution Practice for Medical Devices (GDPMD).

Our Commitment

Pro Element is dedicated to delivering innovative, reliable, and value-driven medical technologies that enhance the quality of patient care. Our focus extends across urology, endourology, and minimally invasive surgical solutions, supporting healthcare providers with trusted products and professional service.

Our Vision

To be a trusted partner bridging global manufacturers and Malaysian healthcare providers—offering medical solutions that combine clinical excellence, technological advancement, and responsive support.

Core Values

Professionalism • Integrity • Service Excellence • Collaboration • Innovation

Booth S37

**QST Technologies (M) Sdn Bhd**

Unit No.10.05, 10th Floor Menara K1, No.1, Lorong 3/137C, Off Jalan Kelang Lama, 58000 Kuala Lumpur, Malaysia.
Tel: +603-7773 3197 / +603-7773 3198 | Fax: +603 7773 3196 | www.qsttech.com | Facebook www.facebook.com/qsttech

QST Technologies was established in 2005 and specializes in providing comprehensive imaging products, services, and solutions, including Ultrasound, MRI, and X-ray systems. We take pride in delivering innovative and effective technologies that meet the growing demands of Urology and Intraoperative Imaging applications.

EXHIBITORS PROFILE

Other sponsorship



Booth S31

**Technology Medical Associate Sdn Bhd**

Lot 2-6, Jalan SU/6A, Lion Industrial Park, Section 26, Shah Alam, 40400, Shah Alam, Selangor, 40400
Tel: +603-5192 9830 | Fax: +603-5192 9793

Technology Medical Associate Sdn Bhd (TMASB), a subsidiary of ABEX Group of Companies established on 1 April 2001, brings over 20 years of leadership and expertise from its management team. TMASB is the official dedicated distributor for Medbot Toumai surgical robotic system in Malaysia, committed to delivering advanced medical technology solutions and exceptional support to healthcare providers nationwide.

The Medbot Toumai system features cutting-edge robotic arms with force-sensing technology, 3D high-definition vision, and intelligent vision algorithms to enhance surgical precision, flexibility, and control. It supports minimally invasive procedures across multiple specialties including urology, general surgery, gynecology, and thoracic surgery. With integrated tele-operation technology and 5G connectivity, Toumai enables remote surgery capabilities, expanding access to high-quality surgical care beyond geographical limitations.

TMASB's partnership ensures access to these advanced surgical innovations that improve patient safety, reduce recovery times, and optimize surgeon workflow efficiency. This commitment aligns with TMASB's vision to be a leader in medical sciences and human capital development, supporting Malaysia's healthcare advancement through technology-driven solutions.

Booth S32

**Transmedic Healthcare Sdn Bhd**

B4-1-1, Solaris Dutamas,, No 1, Jalan Dutamas 1, 50480 Kuala Lumpur, Malaysia.
Tel: +603-6025 3888 | Fax: +603-6205 4062

Transmedic is a leading independent distributor of advanced medical technologies across ASEAN and Hong Kong. With over 40 years of local expertise, we specialise in key therapeutic areas including Blood Therapy, Cardiovascular, In-vitro Diagnostics, Hospital Infrastructure, Neurology, Oncology, Ophthalmology, Orthopaedics, Specialty Pharma, and Spine.

Our regional footprint spans across Singapore (HQ), Malaysia, Thailand, Indonesia, Hong Kong, the Philippines, and Vietnam — partnering closely with healthcare systems to strengthen capabilities, enhance care delivery, and drive meaningful improvements in clinical outcomes across the region.

Within Urology, our portfolio includes advanced solutions such as KOELIS – MRI/PET-CT-Ultrasound Fusion Biopsy System, Targeted Microwave Ablation for prostate focal therapy, Barrigel (Prostate Spacer), Gold Seed (Fiducial Marker), and Deflux (Urethral bulking agent).

Booth S38

**Viatrix Sdn Bhd**

15-03 & 15-04, Level 15, Imazium, No. 8, Jalan SS 21/37, Damansara Uptown, 47400 Petaling Jaya, Selangor, Malaysia
Tel: +603-7733 8005

At Viatrix, access is fundamental to our mission of empowering people worldwide to live healthier at every stage of life. It begins with our ability to sustainably deliver high-quality medicines to people, regardless of geography or circumstance. We are a company uniquely positioned to bridge the traditional divide between generics and brands, combining the best of both to more holistically address healthcare needs globally. Because health matters everywhere. We are access at scale, supplying high-quality medicines to 1 billion patients around the world annually. We have 37 manufacturing/distribution, R&D 37 and packaging sites worldwide and headquartered in the U.S. with global centers in Pittsburgh, Shanghai and Hyderabad, India

Booth S30

**Zuellig Pharma Sdn Bhd**

No. 15 Persiaran Pasak Bumi, Section U8, Perindustrian Bukit Jelutong, 40150 Shah Alam, Selangor Darul Ehsan, Malaysia
Tel: +603-5566 2288

Zuellig Pharma

We are Asia's leading integrated healthcare solutions company, leveraging over a century of expertise to expand access to pharmaceutical and healthcare products through partnerships with manufacturers, governments, and healthcare providers.

Zuellig Pharma Commercialization is a valued healthcare partner for commercialization, innovation, and expanded patient access in Asia. As a trusted healthcare partner, our commercial excellence and in-market capabilities are guided by our ethics and values, centered around our commitment to improving patient journeys and healthcare outcomes.

Conference Information



Conference Venue

Pullman Kuching
Interhill Place, No. 1A, Jalan Mathies,
93100 Kuching, Sarawak, Malaysia
Tel : (+60)82/222888
Fax : (+60)82/222999
Email : H6332@accor.com

Conference Secretariat

33rd Malaysian Urological Conference

Conference Secretariat
Malaysian Urological Association
Unit 6-5, Bangunan Perdagangan D6,
801 Jalan Sentul, 51000 Kuala Lumpur, Malaysia.
Website : www.muc2025.com
Email : malaysianurologicalassociation@gmail.com

Registration Fees Category

Category	Before 01.11.2025	After 01.11.2025
Pre-Congress Workshop 20 November 2025 Pullman Kuching Limit : 150 pax	RM 250	RM 300
Full Delegate Registration 21 & 22 November 2025 Pullman Kuching	RM 1,000	RM 1,100
Nurse and Allied Health 21 & 22 November 2024 Pullman Kuching	RM 650	RM 700

Registration Form

Please return the completed Form to the Secretariat with appropriate fees as early as possible to ensure receipt of the Conference bag and the complete set of conference materials upon checking in at the Conference Registration Desk. Photocopies of the form may be used.

Payment Details

Name of the Account:
The Malaysian Urological Association

Account Number: 514075606138

Bank Address : Myabank, Lot AG 1-2 & AG 9-10,
Block A, Plaza Pekeliling, No. 2, Jalan Tun Razak, 50500 Kuala Lumpur.

Entitlement

Full registrants will be entitled to:

- Admission to all lectures, abstract sessions and symposiums
- Name Badge, Conference bags and Conference materials
- Admission to the exhibition areas
- Coffee/Tea
- Lunches

SEMI LIVE SURGERY WORKSHOP

Date : Thursday, 20 November 2025
Time : 830 - 1700
Venue : Colosseum 1, Pullman Kuching Sarawak

SCIENTIFIC SESSIONS

Date : Friday & Saturday, 21 & 22 November 2025
Time : 0700 - 1700 hrs
Venue : Colosseum 1, Pullman Kuching Sarawak

Robotic Nursing Pre-Congress Workshop

Date : Thursday, 20 November 2025
Time : 0830 - 1700
Venue : Colosseum 2, Pullman Kuching Sarawak

NURSING SYMPOSIUM

Date : Friday, 21 November 2025
Time : 0800 - 1700
Venue : Colosseum 2, Pullman Kuching Sarawak

Breakout Session

MONA LISA ROBOTIC PROSTATE FUSION BIOPSY & NANOKNIFE
ABLATION MASTERCLASS
(Limited to 20 pax)
Date : 21 November 2025
Time : 1045 - 1145
Venue : Taj Mahal, Pullman Kuching Sarawak

Breakout Session

BIOPSEE MRI FUSION PROSTATE FUSION BIOPSY MASTERCLASS
(Limited to 20 pax)
Date : 21 November 2025
Time : 1200 - 1300
Venue : Taj Mahal, Pullman Kuching Sarawak

Breakout Session

KOELIS PROSTATE MRI-FUSION BIOPSY AND TARGETED
MICROWAVE THERAPY MASTERCLASS (Limited to 20 pax)
Date : 21 November 2025
Time : 1400 - 1600
Venue : Taj Mahal, Pullman Kuching Sarawak

Breakout Session

Real-Time Margin Assessment in Robotic Prostatectomy: Initial
Case Experience with the Histolog® Scanner
(Limited to 20 pax)
Date : 21 November 2025
Time : 1615 - 1715
Venue : Taj Mahal, Pullman Kuching Sarawak

Breakout Session

HIFU ABLATION FOR PROSTATE CANCER MASTERCLASS
(Limited to 20 pax)
Date : 22 November 2025
Time : 0815 - 0915
Venue : Taj Mahal, Pullman Kuching Sarawak

Breakout Session

Advancing Miniaturization: Clinical Impact of 6.3Fr fURS in RIRS
Date : 22 November 2025
Time : 0930 - 1030
Venue : Taj Mahal, Pullman Kuching Sarawak

Breakout Session

RIRS MASTERCLASS (Limited to 20 pax)
Date : 22 November 2025
Time : 1045 - 1145
Venue : Taj Mahal, Pullman Kuching Sarawak



**Breakout Session****MINI PCNL & CARBON FUSION BIOPSY SYSTEM MASTERCLASS**

(Limited to 20 pax)

Date : 22 November 2025

Time : 1200 - 1300

Venue : Taj Mahal, Pullman Kuching Sarawak

Breakout Session**BARRIGEL RECTAL SPACER PLACEMENT MASTERCLASS**

(Limited to 20 pax)

Date : 22 November 2025

Time : 1400 - 1500

Venue : Taj Mahal, Pullman Kuching Sarawak

MUA – NAUS RESIDENTS' SESSION

Moderators: Kumarappan Alagappan (Malaysia),

Binod Babu Gharti (Nepal)

Date : 22 November 2025

Time : 0800 - 0930

Venue : Colosseum 2, Pullman Kuching Sarawak

**FEDERATION OF ASEAN UROLOGICAL ASSOCIATIONS
TRAINEES' SYMPOSIUM**

Moderators : William Ong Lay Keat (Malaysia),

Karthika Ramasamy (Malaysia)

Date : 22 November 2025

Time : 1400 - 1530

Venue : Colosseum 2, Pullman Kuching Sarawak

Poster Exhibition

- 1) As an alternative to the traditional printed paper poster, the Malaysian Urological Association is pleased to introduce e-posters to the 34th Malaysian Urological Conference. E-posters will replace the printed posters and we are sure that you will share our enthusiasm for this innovative approach to poster presentation. As you will have uploaded your poster in advance there is no need to print and carry a poster to the meeting. This will save you the time and costs associated with printing and reduce the carbon footprint of the meeting. There will be monitors at the conference where all posters can be viewed.
- 2) Your e-poster should be produced using the Ms Powerpoint Poster template. The content of the presentation should be of a single slide. E-Posters of different dimensions may be skewed/stretched/truncated when displayed on the monitors at the conference unless they conform to the template. The poster should fill up the monitor display when its display is maximised, and not leave any white/black areas. All e-posters will be available for viewing on monitors placed at strategic location.
- 3) All abstracts accepted as **moderated e-posters** will be given a 3-minute podium presentation plus 1-minute discussion slot at the meeting on 22 November 2025. Presenters are required to check the e-Souvenir Programme or Secretariat for the allocated time and venue for the judging session. A template of the Ms Powerpoint slides to be used for the presentation. Moderated posters are eligible for the Best Poster Prize

4) Uploading of presentations will be available at the AV/Speaker Room at Chichen Itza, 0800hr, 21 November 2025 onwards. Presenters are encouraged to upload their presentations at 2000hr on the 21 November 2025.

5) All abstracts accepted as **unmoderated e-posters** can be viewed on monitors placed at strategic location.

Exhibition and Sponsorship

The industry exhibition, open to all registered delegates, forms an integral part of the Conference. Located at Petra Foyer and Pre Function Area, the exhibition provides an ideal opportunity for members of the pharmaceuticals industry, healthcare providers and publishers to discuss the latest products and services available in the field of Urology.

The Conference provides a platform for many high profile promotional opportunities through sponsorship. The Conference Organising Committee would like to express their sincere thanks to the organizations who have so far committed their support to the Event.

21 November 2025	0800hr – 1700 hr
22 November 2025	0800hr – 1700 hr

Insurance and Liability

The Organising Committee will not be liable for personal accidents, loss or damage to private properties of participants during the conference. Participants should make own arrangements with respect to personal insurance

Conference Website

Regularly updated information on registration, hotel reservation and scientific programme are available online at www.muc2025com.

Conference Language

The Official language of the Conference will be English.

Certificate of Attendance

A certificate of attendance will be issued to all delegates.

Letter of Invitation

Upon request, the Organising Committee will issue a letter of invitation. The sole purpose of the letter is to facilitate the delegate's travel and visa arrangements. The invitation does not imply provision of financial support. Letters of invitation may be requested by individuals from the Conference Secretariat by email: maluroassociation@gmail.com

Liability

The Organising Committee will not be liable for personal accidents, loss or damage to private properties of participants during the conference. Participants should make own arrangements with respect to personal insurance.

DISCLAIMER

Whilst every attempt will be made to ensure that all aspects of the Conference published in this announcement will take place as scheduled, the Organising Committee assumes no responsibility should any of these fail to materialize for any reason.

Acknowledgement

The Organising Committee of the **34th Malaysian Urological Conference 2025** expresses its grateful thanks to the following for their contribution and support for the Conference.

Business Events Sarawak (Besarawak)
Ministry of Health Malaysia

GOLD Sponsorship



Astellas Pharma (M) Sdn Bhd
AstraZeneca Sdn Bhd
Boston Scientific (M) Sdn Bhd
Eisai (Malaysia) Sdn Bhd & Merck Sharpe & Dohme (M) Sdn Bhd
GlaxoSmithKline Pharmaceutical Sdn Bhd
Ipsen Pharma (M) Sdn Bhd
Surgimed Tech Sdn Bhd

SILVER Sponsorship



Cook Asia (Malaysia) Sdn Bhd
DTG Medical Sdn Bhd
Evomedic Sdn Bhd
Johnson & Johnson Sdn Bhd
Olympus (M) Sdn Bhd
UMMI Surgical Sdn Bhd & Medi-Life (M) Sdn Bhd

Other sponsorship

Aspen Medical Products Malaysia Sdn Bhd	Lifeways Sdn Bhd
Biobot Surgical Pte Ltd	MEGA Bio-Life
Calmoseptine, Inc.	Mymedic Resources
D'Care Resources Sdn Bhd	Novartis Corporation Sdn Bhd
DCH Auriga Sdn Bhd	Novugen Pharma (Malaysia) Sdn Bhd
Dr. Reddy's Laboratories (M) Sdn Bhd	Orient Europharma (M) Sdn Bhd
Edaptechnomed (M) Sdn Bhd	Pharmaniaga Berhad
Easmed	Pro Element Technology Sdn Bhd
Ferring Sdn Bhd	QST Technologies (M) Sdn Bhd
Getz Healthcare Malaysia Sdn Bhd	Technology Medical Associate Sdn Bhd
H & A Medical Supply Sdn Bhd	Transmedic Healthcare Sdn Bhd
IBS Medical Equipments Sdn Bhd	Viatrix Sdn Bhd
idsMED (M) Sdn Bhd	Zullieg Pharma (M) Sdn Bhd